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THE ROLE OF MIG6 IN PANCREAS DEVELOPMENT 
AND DIABETES 
Diabetes occurs as a result of the failure of pancreatic insulin-producing β cells. 
The preservation or renewal of β cells is a strategy that can prevent diabetes by targeted 
manipulation of mechanisms associated with autoimmune β cell destruction or β cell 
regeneration. ErbB signaling, specifically epidermal growth factor receptor (EGFR) 
signaling, is associated with cell survival, growth, and proliferation. Thus, we 
investigated the role of the ErbB inhibitor, mitogen-inducible gene 6 (mig6), in pancreas 
development and in the progression to diabetes. Using morpholino knockdown in a 
zebrafish model of development, we discovered that mig6 is required for the generation 
of α and β cells as well as the formation of the exocrine pancreas. We suspect that the 
loss of mig6 function causes premature differentiation of ductal progenitor cells, and acts 
as a switch between progenitor differentiation and endocrine transdifferentiation. 
Furthermore, we established a pancreas-specific mig6 knockout mouse that maintained 
glucose tolerance and had a higher β cell mass after chemically-induced β cell injury by 
way of increased β cell proliferation. Our data suggests that mig6 is required during 
pancreas development and may be employed as a switch to direct the production of new β 
cells, but that during adulthood, it is detrimental to the recovery of β cell mass, making it 
a therapeutic target for β cell preservation after the onset of diabetes. 
Patrick T. Fueger, Ph.D., Co-Chair 
Fred M. Pavalko, Ph.D., Co-Chair 
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CHAPTER 1. INTRODUCTION 
 
1.1 Diabetes 
Diabetes is a metabolic disorder of the endocrine pancreas and peripheral target 
tissues. It manifests as abnormally elevated blood glucose levels (hyperglycemia), with 
symptoms such as increased thirst and hunger, frequent urination, and numbness in the 
extremities. Hyperglycemia is detrimental to all other systems, especially the 
cardiovascular and renal systems, and prolonged exposure of these systems to 
hyperglycemia can induce coma and cause death. 
Epidemiology and diagnosis of Type 1 Diabetes 
Diabetes is one of the world’s most common and fastest growing non-
communicable diseases. Globally, an estimated 422 million people were living with 
diabetes in 2014 [1], and in the United States, 23.1 million people were diagnosed with 
diabetes [2]. Both Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D) are defined by 
marked deficiencies in the production or utilization of insulin, the critical blood glucose 
(BG)-lowering hormone required to maintain glucose homeostasis. T2D occurs when the 
body is unable to effectively use the insulin that it produces (i.e., relative insulin 
insufficiency), whereas T1D (previously known as juvenile, insulin-dependent, or 
childhood onset diabetes) is when the pancreas fails to make enough (or any) insulin (i.e., 
absolute insulin insufficiency). T1D accounts for 5-10% of cases of diabetes. This 
dissertation will focus on T1D. 
The symptoms of diabetes include increased thirst and hunger, frequent urination, 
and increased tiredness. Clinically, a patient with prolonged exposure to hyperglycemia 
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presents with hyperphagia (hunger), polydipsia (frequent thirst), polyuria (frequent 
urination), weight loss, and possibly even diabetic ketoacidosis. Diabetes is diagnosed by 
measuring fasting BG levels or based on the HbA1c test, which measures glycated 
hemoglobin over 3 months. The criteria for diabetes diagnosis are any of the following: 
HbA1c ≥6.5%, fasting BG ≥126 mg/dL, a 2h-postprandial BG ≥200 mg/dL, or, in a 
patient with clinical symptoms, a random BG ≥200 mg/dL [2]. After diabetes diagnosis, 
physicians will run more complex diagnostic tests to determine the type of diabetes. 
T1D can be distinguished by the presence of markers like C-peptide, 
autoantibodies, and ketones. During insulin synthesis, preproinsulin is translated into 
proinsulin and processed through the endoplasmic reticulum (ER), where it is modified 
and packaged for transport. Proinsulin is packaged into secretory granules where 
proteases in the granule cleave the protein in two places to excise C-peptide, leaving the 
finished insulin product: two peptide chains linked by two disulfide bonds.  Both the final 
insulin product and C-peptide are released into the blood stream. Thus, C-peptide is a 
marker for insulin production. Unlike insulin, C-peptide is not removed by the liver and 
is eventually excreted into the urine, providing a quantitative measure for insulin 
secretion. For this reason, C-peptide, rather than insulin, levels are commonly used to 
differentiate T1D from T2D, although late stage T2D is also characterized by decreased 
C-peptide levels. 
In addition to this marker, the presence of autoantibodies can confirm T1D 
diagnosis. Autoantibodies are produced by the B cells of the immune system when it fails 
to distinguish between ‘self’ and ‘non-self.’ Autoimmune markers for T1D include islet 
cell autoantibodies (ICA), insulin, GAD/GAD65, tyrosine phosphatases IA-2 and IA-2β, 
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and zinc transporter 8 (ZnT8) [3-5]. These autoantibodies can be present alone or in 
combination, but their correlation is evident, as 93% of young adults with T1D test 
positive for one or more of these autoantibody diagnostic markers [6]. 
Finally, the presence of ketones in the urine is indicative of T1D. Without insulin, 
the cellular uptake of glucose from the bloodstream is markedly reduced. As a result, 
cells such as myocytes and hepatocytes metabolize fat and protein into fatty acids (FAs) 
and amino acids, respectively. In addition, the liver produces more glucose because the 
cells are not receiving the glucose needed to function. The excess glucose signals further 
FA production. The liver then converts FAs into ketones as an alternate energy source 
[7]. Increased glucose and ketones in the blood increases the acidity of the blood (i.e., 
diabetic ketoacidosis) and can prove fatal if untreated. 
Etiology of T1D 
Whereas the rising incidence of T2D correlates with the rise in obesity [8], the 
rise in T1D incidence [9] remains inexplicable. T1D is characterized by the failure of the 
β cell to produce insulin. Suspected etiology of T1D is diverse and ranges from genetic 
predisposition to viral infections and sanitation practices, but progression of the disease is 
likely a concerted effort and, mechanistically, occurs differently in each person based on 
their (epi)genetic milieu [2, 6]. However, definitive findings demonstrate that T1D is 
autoimmune-mediated, meaning, for reasons undefined, the body initiates an immune 
response to endogenous insulin and the pancreatic β cells that produce insulin, resulting 
in insulin deficiency and hyperglycemia [10].  
Of particular interest is the genetic contribution to the onset of T1D. Although 
over 80% of T1D cases occur in individuals with no apparent family history [11], familial 
UI@?A69I$6=$D6:I@$A9>:99$:9;E@6H9I$BD$JE@69=@I$X6@C$!O2$A97B=I@:E@9$@CE@$@C9$:6IS$BD$
A9H9;BJ6=>$A6E89@9I$EH9:E>9I$,r$6=$BDDIJ:6=>L$Zr$6=$I68;6=>IL$E=A$ZNr$6=$6A9=@6FE;$@X6=I$
pOMTOUqQ$"?7E=$FC:B7BIB79$,$FB=@E6=I$C?7E=$;9?SBF<@9$E=@6>9=$`"'/a$>9=9I$@CE@$E:9$
6=HB;H9A$6=$@C9$677?=9$I<I@97dI$E86;6@<$@B$A6I@6=>?6IC$I9;D$D:B7$=B=TI9;DL$E=A$@C9I9$>9=9I$
E:9$A6:9F@;<$FB::9;E@9A$@B$!O2Q$*=F6A9=F9$BD$!O2$6I$@C9$C6>C9I@$6=$@CBI9$9]J:9II6=>$"'/T
2%U$E=AkB:$"'/T2%g$E;;9;9I$E=A$F9:@E6=$"'/T2m$E;;9;9I$EI$6;;?I@:E@9A$6=$1@KOPC!7Q7$p,L$
OZqQ$
!
1@KOPC!7Q7Q$+9=9@6F$I?IF9J@686;6@<$@B$A6E89@9IQ!`&a$"?7E=$FC:B7BIB79$,$FB=@E6=I$"'/$
>9=9IL$E=A$`0a$JBJ?;E@6B=$I@?A69I$:9H9E;$EIIBF6E@6B=$BD$"'/$>9=9I$X6@C$!O2Q!
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Only a 50% concordance between identical twins would suggest that there are 
additive factors to genetic predisposition that are contributing to diabetes onset and 
progression. In fact, external environmental factors are likely to contribute to T1D. 
Candidates for environmental factors include viral infection, geographical region, and 
sanitation practices [6, 16-18]. Viruses are widely suspected of being environmental 
triggers. Enteroviruses are thought to contribute to the pathogenesis of T1D by presenting 
autoantigens and pro-inflammatory cytokines – at least, this theory has dominated the 
field. Enteroviruses are suspected to trigger T1D by molecular mimicry, islet 
inflammation, or inhibition of ductal cell differentiation [19-22]. Geographical location 
may also influence T1D onset. There is evidence of a north-south gradient of disease 
incidence with the highest rate of T1D development in Northern Europe with decreasing 
incidence in southern or tropical climates [23-25]. The hygiene hypothesis to explain the 
rise in T1D also has merit. T1D is more prevalent in highly developed nations that have 
increased sanitation [26, 27]. Additionally, in the experimental non-obese diabetes 
(NOD) mice (the gold standard mouse model of T1D) bred under pathogen-free 
conditions have the highest rate of diabetes development, compared to animals bred in a 
conventional environment [28-30]. 
Following onset of T1D, a series of immunological attacks occur where β cell 
ablation continues. The attack on β cells is largely due to recruitment of autoreactive T 
cells [11] as well as possible progressive destruction of the pancreatic islet depending on 
cyclical patterns of exposure to islet autoantibodies [31, 32]. Due to the cyclical nature of 
antigen presentation, it is suggested that T1D is a relapsing-remitting disease [33], similar 
to designations given to other autoimmune diseases, such as multiple sclerosis or 
,:C9?7E@B6A$E:@C:6@6IQ$!C9$FCE:EF@9:6I@6F$:9F?::9=@$9J6IBA9I$BD$6=D;E77E@6B=$A9IF:689$@C9$
J:B>:9II6H9$A9I@:?F@6B=$BD$@C9$JE=F:9E@6F$6I;9@I$6=$!O2$pgUqQ$
6PIKPCEE@IM!DI!'7"!
e$F9;;$A9I@:?F@6B=$6=$!O2$J:B>:9II9I$BH9:$@679$E=A$BD@9=$=B$I<7J@B7I$J:9I9=@$
?=@6;$F:6@6FE;$e$F9;;$7EII$6I$:9EFC9AQ$e$F9;;$7EII$6I$@C9$:9;E@6H9$J9:F9=@E>9$BD$e$F9;;$E:9E$
7?;@6J;69A$8<$@B@E;$JE=F:9EI$7EIIQ$e$F9;;$7EII$6I$;BI@$6=$E$I@E6:TI@9J$7E==9:$pggL$gZqQ$
0CE=>9I$6=$e$F9;;$7EII$A?:6=>$!O2$J:B>:9II6B=$E:9$I?77E:6_9A$6=$1@KOPC!7Q9Q$.9:IB=I$
>9=9@6FE;;<$I?IF9J@68;9$@B$!O2$E:9$9]JBI9A$@B$B=9$B:$7B:9$9=H6:B=79=@E;$DEF@B:I$@CE@$
6=6@6E@9$E=$E?@B677?=9$E@@EFSL$:9I?;@6=>$6=$E$;BII$BD$e$F9;;$7EIIL$?=@6;$I<7J@B7I$J:9I9=@$
E=A$A6E89@9I$6I$A6E>=BI9AQ$2?:6=>$@C9$J9:6BA$89@X99=$A6E>=BI6I$E=A$FB7J;9@9$e$F9;;$
A9I@:?F@6B=L$@9:79A$@C9$CB=9<7BB=$JCEI9$pg,qL$@C9:9$6I$:9I6A?E;$e$F9;;$7EIIQ$0?::9=@$
:9I9E:FC$79E=I$@B$@ES9$EAHE=@E>9$BD$@C9$CB=9<7BB=$J9:6BA$EI$E=$6=@9:H9=@6B=$X6=ABX$@B$
6=@:BA?F9$6=I?;6=B@:BJ6F$E>9=@I$B:$e$F9;;$:9I@B:E@6B=$79@CBAI$@B$J:B;B=>$B:$6=F:9EI9$
9=AB>9=B?I$e$F9;;$D?=F@6B=$pghqQ$
1@KOPC!7Q9Q$-E@?:E;$C6I@B:<$BD$!<J9$O$26E89@9I$#;#<6:;&=9(-&>?@A+&
7 
Management and current therapies 
Current management strategies for T1D are intensive insulin therapy and β cell 
replacement via transplantation. Human islet transplantation has been extensively 
assessed as a means to cure T1D, with outcomes of 3- to 5- year-long insulin 
independence in almost half of transplanted patients [38]. However, translation of this 
procedure to routine clinical treatment has been restricted by donor organ shortage and 
the need for long-term immunosuppression drugs [39]. 
The majority of patients with T1D manage blood glucose levels by administration 
of exogenous insulin, an arduous and expensive endeavor over the lifetime of a patient. 
Patients often have bouts of burnout, which may affect adherence to treatment strategies 
established between the patient and their healthcare providers. It is pertinent to identify 
alternative treatment strategies. Studies have largely focused on the immune response, 
but, to date, immunological treatments have been largely ineffective [40]. Instead, 
cellular therapies are a growing alternative that can promote β cell proliferation, survival, 
and recovery [41]. These therapies may be useful in restoring β cell mass during the 
honeymoon period to delay insulin dependence. 
 
1.2 Pancreas development and function 
Key elements to the restoration of β cell mass may be uncovered by 
understanding the origins and cross-talk of the pancreatic endocrine cells that regulate 
glucose homeostasis. To elucidate these origins, we explore genes in the context of 
pancreas development and organogenesis. Work in this area may reveal transcription 
factors that control cell fate, and can be utilized for in vitro pancreatic differentiation. 
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Transcription factors decide endocrine cell commitment 
The pancreas forms from two buds – the dorsal and ventral buds – that are formed 
from the distal foregut endoderm. At the final stage of pancreas specification, the 
different cell types in the pancreas can be distinguished by their transcription factor 
expression profiles. Human embryogenesis (fertilization until 8 weeks post conception 
[wpc]) is divided into 23 Carnegie Stages (CS). As presented in Figure 1-3, the various 
cells types that arise in the human pancreas have distinct cell lineages. These 
transcription factors can be used to differentiate cells in vitro to create β cells or β-like 
cells for transplant or drug screening [42-44]. Human pancreatogenesis is similar to 
mammalian models of pancreas development, but transcription factor expression varies.  
Pancreas and duodenum homeobox 1 (Pdx1) and Pancreas transcription factor 1a 
(Ptf1a) are the main initiators of pancreas differentiation. Pdx1 is expressed throughout 
pancreas development and its expression does not wane until maturation of late 
progenitor cells into duct or endocrine cells [45, 46]. In fact, knock out of Pdx1 results in 
absence of pancreatic tissues [47] and impeded pancreatic progenitor expansion, but β-
like and α-like cells persist [48], indicating that Pdx1 is not necessary for early 
differentiation of endocrine cells. However, Pdx1 is crucial for β cell function and 
maintenance of β cell maturity. Pdx1 expression is progressively confined to the 
endocrine β cell [49] and, in mature β cells, reduction of Pdx1 depletes insulin and 
induces glucose intolerance [50], suggesting that Pdx1 is required to maintain normal β 
cell function. 
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transactivates the Pdx1 gene [52, 53], suggesting that the mutual actions of Ptf1a and 
Pdx1 are crucial for early foregut progenitors to acquire a pancreatic cell fate [54]. 
With time, Pdx1 and Ptf1a are restricted to the acinar progenitor cells, while Sox9 
and Nkx6.1 are expressed in the bipotent progenitors of the trunk giving rise to both duct 
or endocrine cells [55].  Eventually, some trunk progenitors will increase expression of 
Neurogenin3 (Ngn3), resulting in endocrine cell differentiation. Loss of Ngn3 results in 
complete absence of α, β, δ, and pancreatic polypeptide endocrine cells [56], supporting 
the governing role of Ngn3 in endocrine cell specification. Endocrine cell fate in the 
pancreas is also decided by MafA, which is increasingly expressed over the course of 
pancreas development. Loss of MafA results in impaired glucose stimulated insulin 
secretion (GSIS), abnormal islet morphology, and diabetes [57]. Together, 
overexpression of Pdx1, Ngn3, and MafA causes pancreatic exocrine progenitors to 
become β-like cells. 
Endocrine hormones regulate endocrine cell development 
Differentiated endocrine cells feedback to progenitors to facilitate cell 
differentiation. Studies in the glucagon-producing α cells have indicated that knock down 
of the glucagon gene in zebrafish facilitated α to β cell transdifferentiation, suggesting 
that glucagon gene products act as permissive signals to disrupt α cell stability [58]. In 
fact, GLP-1 (an incretin hormone derived from the pre-proglucagon gene and secreted 
primarily by the intestinal enteroendocrine L cells) is implicated in the protection and 
promotion of β cell regeneration through paracrine signaling between adjacent α cells and 
injured β cells [59]. Although the exact mechanism of β to α cell cross talk is not well 
defined, α cell proliferation is proposed to contribute to α cell hyperplasia observed in β 
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cell injury models [60]. This expansion of α cells provides an enlarged pool for α to β cell 
transdifferentiation. 
 
Table 1-1. Pancreatic cells and their physiological functions 
Pancreas 
type 
Cell  Secretes Physiological Function 
Endocrine β  insulin, amylin lowers blood glucose  
α glucagon raises blood glucose  
δ somatostatin decreases GI functions, inhibits 
glucagon and insulin secretion*  
F (PP) pancreatic 
polypeptide 
reduces gastric acid secretion, increase 
intestinal nutrient transit times, inhibits 
postprandial exocrine pancreas 
secretion  
ε ghrelin enhances GSIS*, stimulates hunger  
Exocrine acinar digestive enzymes 
in H+-rich fluid 
nutrient breakdown, induces alkaline 
fluid production by duct cells  
duct alkaline buffer 
fluid 
neutralizes both gastric acid entering 
duodenum and acidic acinar digestive 
enzymes, and facilitates fluid 
movement to flush pancreatic enzymes 
into duodenum 
*supposed function 
 
Function of endocrine versus exocrine pancreas 
Lineage tracing experiments in rodents have demonstrated that Pdx1-expressing 
progenitors give rise to all three pancreatic cell-types: exocrine, endocrine, and duct [61, 
62]. The exocrine pancreas secretes enzymes into the intestine whereas the endocrine 
pancreas secretes hormones into the bloodstream. Table 1-1 lists the pancreatic endocrine 
and exocrine cells and their physiological functions. Endocrine cells are sensors and 
regulators of glucose homeostasis and are responsible for maintaining blood glucose 
within normal physiological levels (in humans, 70-130 mg/dL). Glucose homeostasis is 
mainly regulated by the actions of two opposing cell types: β cells and α cells. Insulin 
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decreases blood glucose levels by promoting glucose uptake into peripheral tissues. 
Glucagon increases blood glucose by stimulating breakdown of glycogen to glucose in 
the liver and activating gluconeogenesis [63]. Insulin also suppresses the production of 
glucose by the liver.  Glucose homeostasis is a precise physiological balance that, when 
disrupted, causes unregulated blood glucose and diabetes. 
 
1.3 Autoimmunity and β cell destruction 
Autoimmune destruction of the pancreatic insulin-producing β cells embodies 
T1D. As briefly mentioned above, progression to overt T1D involves a myriad of 
circumstances to promote β cell necrosis and apoptosis.  
Autoimmune pathology 
In this section, the components of the immune system and their effect on β cell 
mass are explained in more detail. β cell destruction in T1D begins with an 
environmental trigger that activates autoimmunity. Normally, through a process known as 
tolerance, the immune system is trained to identify and ignore the body’s own cells (i.e., 
self), but must concurrently identify and fight foreign cells that pose a threat (i.e., non-
self). Foreign antigens are enveloped and presented on the surface of professional 
antigen-presenting cells (such as dendritic cells and B cells) by major histocompatibility 
complexes (MHC) class II molecules, initiating an immune response to the foreign 
antigen [64]. When the immune system fails to distinguish ‘self’ from ‘non-self,’ it 
produces autoantibodies to specific ‘self’ antigens. Testing positive for all three 
autoantibodies to GAD65, IA-2, and insulin is highly predictive of diagnosis of T1D [3, 
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5]. Presentation of GAD65, IA-2, and insulin causes insulitis, whereby immune cells are 
recruited to the islet, infiltrate it, and attack the β cells. 
In T1D, it is hypothesized that tolerance to self-antigens expressed in the islets 
fails to develop or persist [65]. The previously mentioned NOD mouse is frequently used 
as a model of T1D because it spontaneously develops diabetes. The implications of 
immune tolerance on autoimmune diabetes are exemplified in the following study 
demonstrating that in proinsulin conditional knock out NOD mice, enhancing tolerance to 
proinsulin during the period from gestation to weaning was sufficient to protect against 
diabetes in the long-term [66]. Although the exact mechanism of T cell antigen 
presentation is poorly defined, it is widely supported that differential affinity for thymic-
presented self-antigens determines whether potential auto-reactive T cells are deleted or 
converted to regulatory T cells (Tregs) during thymus development [66-69]. An 
alternative explanation that supplements the T cell receptor affinity hypothesis has slowly 
gained popularity as a complement to the affinity model. This alternative hypothesis was 
first proposed in the 1980s [70] and presented the idea that mutations in islet antigens 
may prevent the clonal deletion of autoreactive T cells in the thymus, and evidence has 
been collected to support this idea [71]. Unfortunately, immunological therapies targeting 
immune suppression and tolerance have yet to translate into effective long-term therapies 
for humans [40]. Alternatively, investigations into cellular therapies have promising 
results and may be administered in combination with immunological therapies or other 
cellular therapies [72]. Therefore, scientists continue to unravel the mechanisms of 
autoimmunity to develop better cellular therapies.  
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Cytokine signaling 
One mechanism of focus concerning immune cells is the release of pro-
inflammatory cytokines into the islet by CD4+ and CD8+ autoreactive T cells, which 
causes β cell death [67, 73-75]. Cytokine signaling is well known to contribute to β cell 
death, but the cytokines IL-1β, TNF-α, and IFN-γ that are released by T cells and 
macrophages have a more finessed role in the progression to T1D. Pro-inflammatory 
cytokines are crucial to development of diabetes. For example, neutralization of IL-1β, 
IFN-γ, IL-6, and TNF-α can inhibit the spontaneous development of diabetes in NOD 
mice [76]. 
Cytokines have a variety of effects on β cells. They sensitize β cells to apoptosis 
by expressing pro-apoptotic proteins [77]. They facilitate the autoimmune response and 
attack by triggering suicidal secretion of chemokines by β cells, resulting in continuous 
recruitment of autoreactive T cells [78]. Lastly, cytokines cause direct stress to the β cell. 
These effects ultimately activate the cell’s death machinery. However, any pro-
inflammatory cytokine alone has somewhat limited effects on cell stress or β cell death; 
however, in combination, they have very strong effects that induce enough stress to lead 
to cell death [79]. This response is probably mediated by nitric oxide (NO production). 
NO production can be measured by nitrite levels in cytokine-treated human islets. Nitrite 
production in human islets increased in conditions where islets were exposed to multiple 
cytokines, with the most nitrite produced when islets were treated with the combination 
of pro-inflammatory cytokines, IL-1β, TNF-α, and IFN-γ [80]. 
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Immune-mediated loss of functional β cell mass 
In response to the rise in cytokine-facilitated cell death, the islet compensates by 
increasing β cell proliferation. However, eventually the β cells become overwhelmed, the 
islet degranulates and compensatory β cell function ceases, impairing glucose tolerance, 
decreasing insulin secretion, and reducing overall β cell mass [37]. Functional β cell mass 
is regulated by the balance between β cell expansion (e.g., proliferation, 
transdifferentiation, and neogenesis) and destruction (e.g., death and dedifferentiation).  
Autoreactive immune cells in diabetes persist after diagnosis and management of 
symptoms. This concept was implied in a series of clinical trials in the 1980s revealing 
that cyclosporin therapy led to remission of T1D, but only when administered within 
months of disease onset when there was residual β cell mass to maintain glucose 
homeostasis [81-83]. The toxicity of drugs such as cyclosporin prevented its approved 
use for the treatment of T1D. Consequently, when cyclosporin therapy ceased, T1D 
relapsed rapidly [84, 85]. These studies revealed that (safer and more targeted) immune 
suppression could be an effective treatment for T1D, but immunotherapies developed 
since have proven ineffective in the long-term.  
 
1.4 Mitogenic signal control of functional β cell mass 
Cellular therapies are gaining attention as promising alternatives to ineffective 
immunological treatments. Mitogenic signaling induces mitosis. Mitogens like insulin, 
glucose, incretins, insulin-like growth factor, epidermal growth factor (EGF), and HGF, 
have been demonstrated to increase β cell expansion [86-89]. However, there is a gap in 
the understanding of how mitogenic signaling is regulated. 
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ErbB receptor tyrosine kinase signaling 
The ErbB receptor family has four members: the EGF receptor (EGFR, known as 
ErbB1), ErbB2, ErbB3, and ErbB4. Generally, each receptor consists of an extracellular 
binding domain (except ErbB2), a transmembrane domain, and an intracellular kinase 
domain (except ErbB3) [90]. Upon ligand binding, the ErbB receptors either homo- or 
heterodimerize to active the intracellular domain, leading to recruitment of adapter 
proteins to activate ERK and PI3K signaling [91]. 
EGF and EGFR 
Specifically, EGFR signaling controls key cell fate programs, including cell 
survival, proliferation, and differentiation [92]. EGFR and its ligand, EGF, have been 
implicated in increased β cell mass and protection against diabetes. EGFR is also 
essential for normal pancreatic development and postnatal β cell proliferation [93-96]. 
Mice with constitutively active EGFR treated with the β cell toxin streptozotocin (STZ) 
were protected from hyperglycemia, had a higher survival rate, and higher β cell mass 
compared to control animals [97]. Conversely, mice expressing a dominant-negative 
EGFR developed diabetes within 2 weeks of birth, had lower insulin levels, and had 
fewer islets compared to control mice [95].  
As a cellular therapy, EGF and gastrin in combination dampened hyperglycemia 
in STZ-treated rats [98]. In addition, administration of EGF and gastrin increased β cell 
mass and reversed hyperglycemia in NOD mice [99]. However, this therapy has yet to 
translate into a viable treatment for humans [100]. EGF therapy also raises concerns 
around specificity of β cell expansion, as some non-specific signals could promote 
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inadvertent growth of other cells. This unwarranted effect can be avoided by indirectly 
targeting EGFR through targeting its negative regulators. 
Inducible feedback inhibition of EGFR 
The EGFR signaling cascade is one of the most investigated molecular pathways 
in regulation of cell fate. Thus, to ensure proper signaling, EGFR activity is tightly 
controlled by a number of negative regulators, as a built-in security feature [101, 102]. Of 
these various regulatory programs, EGFR is subject to four mechanisms of inducible 
feedback inhibition by leucine-rich immunoglobulin-like domains protein 1 (LRIG1), 
suppressor of cytokine signaling 4 and 5 (SOCS4 and SOCS5), and mitogen-inducible 
gene 6 (Mig6) [103]. These inhibitors bind to EGFR directly and suppress EGFR 
signaling, but they also bind other members of the ErbB family and are considered 
collective ErbB inhibitors. LRIG1, SOCS4 and SOCS5 half-life data suggests 
transcriptional and post-transcriptional control mechanisms that confine inhibitor 
expression to a window of a few hours [103], which could be extrapolated to Mig6 but 
direct studies on its half-life during EGFR activation are absent. 
LRIG1 and SOCS4 have not been associated with metabolic disease, and SOCS5 
has been loosely implicated (by association with the Jak/Stat pathway) with neuronal and 
cognitive function in diabetes [104]. Meanwhile, for Mig6, there is compelling evidence 
of metabolic effects in rodent models of diabetes [105-107]. 
Mitogen-inducible gene 6 (Mig6) 
Mig6 is a catalytically inert 50 kDa protein containing an EGFR binding domain, 
a CRIB domain, a 14-3-3 protein binding motif, and a GRB2 binding motif [108]. Of 
note, the GRB2 motif contains SH2 and SH3 binding domains designed to bind Grb2, Src 
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kinase and phospholipase C γ (PLC-γ) (Figure 1-4 A). Mig6 transcription is rapidly 
induced by mitogens (such as EGF, HGF, and insulin) and stress stimuli (such as 
cytokines and hypoxia) [105]. 
Dimerization and activation of the EGFR induces Mig6 to bind all ErbB family 
members and inhibit tyrosine kinase activity. Mig6 is thought to function with two 
mechanisms to control EGFR signaling. First, by binding between the two EGFR kinase 
domains and preventing kinase activation [108] and second, by promoting protein 
scaffolding interactions that lead to internalization of the receptor [109, 110]. A 
simplified schematic in Figure 1-4 B illustrates Mig6 inhibitory mechanisms described 
above. 
Mig6 has fairly ubiquitous expression patterns in adult human tissue, but is 
differentially expressed in embryonic tissues, with higher expression in the heart, 
fibroblasts, ovary, thyroid, pancreas, and liver (RNASeq data, GeneCards). Indeed, whole 
body Mig6 knock out mice have 50% embryonic lethality, and those that survive have 
abnormal lung development as measured by decreased ductal growth, density and 
branching [111]. Although there are few studies centered on Mig6 and development, the 
importance of EGFR signaling in development is well-established [92, 93, 97, 112], and 
substantiates the importance of Mig6 in development. 
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Activation and priming of Mig6 
Mig6 is induced by ER stress, glucolipotoxicity, and pro-inflammatory cytokines 
[105-107]. The mechanism(s) through which cytokines induce Mig6 expression, like 
EGFR inactivation, are unclear. Mass spectrometry has recently uncovered 
phosphorylation of Mig6 on several residues, including Ser251, Ser256, Tyr394, Tyr395 
[111-115], suggesting that Mig6 is subject to post-translational control. A study recently 
confirmed tyrosine phosphorylation of Mig6 and suggested an activated Src family 
kinase (SFK) was involved [113]. There are 9 members of the SFKs [116] listed in Table 
1-2. Each of the SFKs share similar structural features including a Src homology domain. 
Functional redundancy among members of the SFKs makes identification of the specific 
role of each Src kinase difficult. The activation of SFKs by many diverse families of 
receptors induces cellular responses that affect growth control, survival and 
differentiation, cytoskeletal arrangements, secretion, channel function and other 
biological activities [117]. 
Src, a non-receptor tyrosine kinase, is one of the most studied members of the SFKs, 
and has been implicated in proliferation, survival, apoptosis and differentiation [118]. Src 
is activated by receptor tyrosine kinases, like EGFR, as well as other stimuli that are altered 
in diabetes pathogenesis, such as G-protein coupled receptors, TGF-b, and reactive oxygen 
species (ROS) [119-121]. In fact, EGF treatment induces a two- to threefold increase in 
Src catalytic activity [122]. Additionally, it was demonstrated that treatment with IL-1β 
and TNF-α increased Src activation in human brain (T98G) and muscle (HTSM) cells, 
respectively [123, 124]. 
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Table 1-2. The nine Src family kinases 
SFK Expression [125] Selected Functions [117, 126-146] 
Src Ubiquitous, two neuron-specific 
isoforms 
Cell adhesion 
Focal adhesion dynamics 
Cell migration 
Integrin-induced MAPK activation 
Cell cycle progression 
Differentiation reviewed in [138] 
Fyn Ubiquitous, T cell-specific 
isoforms 
Focal adhesion dynamics 
T cell development 
Cell cycle progression 
Yes Ubiquitous Cell cycle progression 
Lyn Brain, B cells, myeloid cell; two 
alternatively spliced forms 
Apoptosis promotion or prevention* 
Hck Myeloid cells, bone Bone remodeling 
Fgr Myeloid cells, B cells, blood, 
bone, spleen 
Apoptosis promotion or prevention* 
Blk B cells, lymph node, spleen, 
appendix 
B cell receptor signaling, B cell 
development, stimulates insulin synthesis 
and secretion in response to glucose and 
enhances the expression of pancreatic β 
cell transcription factors [147] 
Lck T cells, NK cells, brain, thymus T cell migration and maturation, 
Apoptosis+[117] 
Frk Epithelial cells Cell cycle suppression [125] 
*ambiguous function, +speculative function 
 
Although it has traditionally been referred to as an adapter protein, 
phosphorylation (‘priming’) of Mig6 on tyrosine residues 394 and 395 suggests it is 
subject to its own regulatory mechanism. The interplay among Src activation, Mig6 
activation, and EGFR inactivation, all mediated by pro-inflammatory cytokines and ROS, 
has yet to be investigated. Src kinase is a likely candidate for Mig6 regulation and 
warrants further study to fully understand mitogenic signaling and its potential in 
expansion of β cell mass. 
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1.5 β cell regeneration 
Strategies to promote β cell regeneration during the progression to T1D can be 
used to restore functional β cell mass. During development, β cell neogenesis occurs to 
increase β cell mass in fetuses. Understanding of this process may be transferred to 
current work on stem cell-derived β-like cells for transplantation or drug development. 
Another area of focus is the immunological attacks and triggers and how it can be 
targeted to altogether prevent the loss of β cell mass. Lastly, there is significant work 
around restoring lost β cell mass from endogenous sources, which may include recycling 
developmental mechanisms to regenerate β cell mass after diabetes onset. 
Clinical instances of human β cell regeneration 
Pancreas sections obtained from autopsy in healthy and T1D patients reveal that 
there are β cells present in the majority of patients with longstanding T1D, and that β cell 
number does not correlate with duration of disease, which was the case even though the 
number of β cells undergoing apoptosis was doubled in T1D islets [148]. Presence of 
scattered single β cells and β cells within islets from T1D pancreas samples has also been 
reported [149, 150]. Moreover, in the unique case of an 89-year old patient who was 
recently diagnosed with T1D and received a pancreatectomy, cellular immunostaining 
not only confirmed that β cell apoptosis is an important mechanism in T1D-mediated β 
cell destruction, but also that β cell regenerative mechanisms are initiated in recently-
onset T1D [151]. 
Endogenous sources of in vivo β cell regeneration 
Current advances in islet replacement therapy have been shown to reverse 
diabetes in 88% of patients at 1 year and 71% at 2 years, but by 5 years post-
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transplantation, only 10% of patients remain insulin independent [152, 153]. The surgery 
costs about $20,000 and pooled islets from several donors are transplanted into one 
patient with T1D. Therefore, cadaveric islet transplantation is not a suitable widespread 
treatment because the ratio of available donors to potential patients is too small and too 
costly to repeatedly treat the general population. In addition, chronic immunosuppression 
is required for success of the transplant, which can also produce unwarranted effects such 
as tumors and insomnia [154]. Instead, treatment for the general population is intensive 
insulin therapy. While insulin therapy has drastically improved outcomes for patients 
with T1D, compared to exacting biological islet cells, it is a crude means of controlling 
BG levels and often is accompanied by hypoglycemia. Strategies that mine endogenous 
pools of insulin-producing cells are increasingly attractive to replace β cells and attain 
physiological BG control [155]. Such strategies include β cell proliferation of existing 
endocrine cells, differentiation of embryonic stem cells (ESCs) to β cells, or 
transdifferentiation of exocrine stem/progenitor cells into β cells [156-159]. 
Proliferation of existing β cells is thought to be one endogenous source of β cell 
replenishment. Significant efforts went into identifying compounds that could stimulate β 
cell proliferation, resulting in identification of several compounds that are capable of 
stimulating β cell expansion in rodent islets [160-162]. Although it was found that newly-
onset diabetes manifested in increased β cell death, there is only some evidence that the 
proliferative regeneration program, specifically, is present in the human pancreas [163]. 
Neogenesis is the formation of new islets cells from pancreatic progenitors 
(Figure 1-3) and is accepted as the method of initial β cell expansion during 
embryogenesis [157]. Whether these pancreatic progenitors retain their plasticity into 
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adulthood is a subject of some controversy, but several studies support that they do retain 
some degree of plasticity. For example, GLP-1 receptor agonists have been reported to 
induce β cell replication and β cell neogenesis from pancreatic progenitor cells in adult 
rodent models [164]. It was also demonstrated that acinar cells, which represent a major 
proportion of the developed pancreas, can transdifferentiate into insulin-producing cells 
[165]. ESCs and induced pluripotent stem cells represent the most widely investigated 
candidates for in vitro reprogramming because they can theoretically proliferate forever 
and have a high potential to differentiate [157].  
The pancreatic ducts also possess a potential subgroup of cells that can give rise 
to insulin-producing cells in vitro [166, 167]. Much evidence exists supporting β cell 
regeneration from the duct epithelium [38, 168, 169]. For instance, in human and mouse 
cells, it was demonstrated that cells within the pancreatic ductal gland proliferate and 
commit to β-like cells under high glucose conditions [170]. Also, lineage tracing of 
EGF/gastrin-regenerated β cells found that the new β cells were budding from the duct 
during postnatal development [99]. This particular pool of progenitor cells represents a 
promising source of cells that can be made into β-like cells in vitro by targeted delivery 
of crucial transcription factors. 
Zebrafish as a model for pancreas development and β cell regeneration 
Zebrafish are a convenient model for pancreas development because they are easy 
to manipulate genetically, they are relatively inexpensive, embryos can be quickly 
collected in large quantities year-round, and they have β cell regeneration capabilities 
[171, 172]. Furthermore, of particular importance, the pancreatic developmental program 
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as well as actions of glucose regulating proteins (insulin, glucagon and others) are highly 
conserved between mammals and zebrafish [173-176]. 
As described previously, transcription factors determine cell specification in 
human pancreas development. As in mammals, zebrafish pdx1 and ptf1a are necessary 
for regulating pancreatic progenitor differentiation, and its expression can be tracked in 
the developing pancreas tissues: from dorsal bud progenitors at 12 hpf to β cells at 24 
hpf, and finally to the ventral pancreas after ventral bud specification, where they remain 
to maintain acinar cell identity [177]. neurod1, arx, nkx2.2, pax6, mafa are all conserved 
transcription factors as well. Curiously, whereas rodent Ngn3 is required for β and α cell 
specification, zebrafish ngn3 is not required for endocrine cell formation. Ngn3 function 
appears to be replaced in zebrafish by ascl1b; ascl1b, together with neurod1, regulates 
differentiation of pancreas progenitor cells into endocrine cells [178]. Altogether, 
zebrafish have conserved endocrine cell development and represent a unique and relevant 
model of the mechanisms involved in pancreas development. 
Zebrafish also have the capacity to regenerate β cells after chemically-induced 
islet ablation [172, 179]. Some of the differentiation mechanisms described above may be 
involved in the regenerative capacity of zebrafish. Specifically, Figure 1-5 depicts duct 
progenitor cell differentiation into endocrine cells and their migration to the principal 
islet of zebrafish during early pancreas specification. A β cell ablation and regeneration 
model using transgenic lines expressing nitroreductase (NTR) in insulin-producing cells 
is a powerful tool to study β cell regeneration. The reduction of NTR and its products’ 
reaction with metronidazole (MTZ) produces a cytotoxic environment in the NTR-
expressing β cells causing both ROS generation and cross-linking of DNA strands that 
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induces β cell death [172, 180]. After a period of recovery, β cell regeneration can be 
precisely quantified and origins of those cells can be simultaneously studied by lineage 
tracing studies.  
 
 
Figure 1-5. Schematic diagram of β cell regeneration and migration from progenitor cells 
in the zebrafish. EPD; pancreas = P, principal islet = Pi, extrapancreatic duct = EPD, 
extrahepatic duct = EHD. endocrine cells = red, progenitor cells = blue+green 
 
To summarize, we perceived a gap in understanding of Mig6 regulation and 
control mechanisms. Mig6 has potential therapeutic applications to increase functional β 
cell mass via indirect EGFR manipulation. Given the extensive impact of EGFR 
signaling on developmental pathways and protection against diabetes, we suspected that 
Mig6 had an important function in pancreas development and in the progression to 
diabetes. Notably, cytokines 1) induce Mig6 expression and 2) stimulate β cell death and 
leads to loss of β cell mass during the progression to diabetes. We propose that cytokine-
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induced Mig6 results in a loss of EGFR signaling which impedes β cell regeneration in 
the immune cell infiltrated islet. 
 
1.6 Aims and Hypotheses 
We aimed to investigate the role of Mig6 in development and identify the 
molecular events by which Mig6 affects β cell mass during the progression to diabetes. 
We used a zebrafish model of development to study Mig6 during pancreatogenesis and 
based on observed abnormalities in the ducts of Mig6 knock out mice [181], we 
hypothesized that loss of Mig6 increases EGFR activation in the duct, causing early 
differentiation of duct progenitor cells, thereby decreasing potential β cell regeneration. 
We investigated a proposed mechanism of Mig6 regulation by inhibiting Src kinase in the 
832/13 cell line, hypothesizing that cytokines induce Mig6 expression via activation of an 
SFK. Finally, we reinforced these data by characterizing Mig6 pancreas-specific knock 
out mice and elucidating the mechanism of EGFR inactivation resulting from cytokine-
induced Mig6. We hypothesized that cytokine-induced EGFR inactivation by Mig6 
accelerates the loss of β cell mass by blocking endogenous regenerative mechanisms.  
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CHAPTER 2. DIFFERENTIAL REGULATION OF DUCTAL 
NETWORKS BY MIG6 DURING ZEBRAFISH DEVELOPMENT 
 
2.1 Summary 
Strategies to promote β cell neogenesis could be used to restore functional β cell 
mass in diabetes. We examined the role of mig6 in the regulation of functional β cell 
mass. mig6 is evolutionarily conserved and encodes a protein that inhibits the EGFR in a 
classic feedback mechanism, suggesting a potential role in cellular growth and 
development. Based on functional studies in mouse and human, we hypothesized that 
mig6 is required in pancreatic ducts for pancreatogenesis and β cell function. We used 
morpholino knock down in zebrafish to define the role of mig6 in both exocrine pancreas 
and islet development. We established that mig6 knock down (mig6MO) embryos have a 
disrupted pancreas morphogenesis, particularly, a truncated exocrine pancreas and fewer 
intra-pancreatic duct cells. Additionally, mig6MO-injected animals had fewer α and β 
cells than controls. 
Our data led us to hypothesize that mig6 may facilitate the expansion of the 
pancreas progenitor pool by blocking EGFR activation. We further investigated the role 
of mig6 in islet regeneration. Neogenic β cells may arise from two sources in the 
developing zebrafish, which can be distinguished by the retention of a fluorescent mark 
made at the one-cell stage. β cells derived via transdifferentiation from other post-mitotic 
endocrine cells remain labeled, whereas those derived from duct-associated progenitors 
lose their label via proliferation. Together, our data demonstrate that mig6 is essential for 
pancreas development and that it might be exploited as a switch between progenitor 
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differentiation and endocrine transdifferentiation to increase β cell mass in diabetic 
patients. 
 
2.2 Introduction 
Both T1D and T2D are characterized as the loss of the insulin-producing 
pancreatic β cells, demonstrated by a reduction in functional β cell mass. Functional β 
cell mass may be restored through methods such as α to β cell transdifferentiation, β cell 
proliferation, and β cell neogenesis [182]. To restore β cell mass from undifferentiated 
cell types, it is essential to understand what controls the fate of the pancreatic and duct 
progenitor cells. Human pancreatogenesis studies have revealed several of the crucial 
transcription factors directing β cell differentiation and neogenesis, including MAFA, 
PDX1, PTF1A, PAX6, NGN3, FOXA2 and insulin. However, our understanding of the 
generation of β cells in human is limited due to the challenge of establishing primary cell 
lines of these progenitors yielding to long term cell culture and adaptation.  
EGFR signaling has been intensively studied during both development and the 
progression to diabetes. EGFR knock out mouse embryos have a smaller pancreas [94] 
and EGFR is required for ductal growth, density and branching in mouse mammary 
glands [183]. As a feedback inhibitor of EGFR signaling, mig6 is an obvious candidate 
for roles in pancreas and duct development. In fact, during development, mig6 seems to 
be crucial for branching in the lung [184], an organ whose proper function requires an 
extensive ductal network. An extensive ductal network is also essential in the liver and 
pancreas. To this end, manipulating EGFR-mediated cell survival and proliferation in the 
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pancreas by targeting mig6 may play a role in maintaining euglycemia and regenerating β 
cells. 
Developmental studies utilize the diverse and widely applicable zebrafish model 
because of the short gestation period, whole mount visualization of genes and proteins, 
and easily manipulated gene expression. A potential source of regenerated β cells in 
humans and various animal models is the differentiation of ductal network endocrine 
progenitor cells [182, 185]. Numerous in vivo rodent studies have revealed evidence that 
pancreatic ducts are a source of progenitor cells [38]. Findings that lead to this 
understanding included partial pancreatic tissue regeneration from ductal cells [186], 
appearance of β cell clusters from ductal epithelium 3-days post 90% pancreatectomy 
[187], and the conversion of duct specific Sox9+ cells into insulin-producing cells after 
the combined treatment of EGF and gastrin [188]. After β cell injury, embryonic 
zebrafish can restore β cells, and within 3 to 4 days recovery time, can regenerate β cells 
to restore normal islet function and much islet architecture [179, 189]. In the zebrafish, 
studies propose that a component to this regeneration utilizes the natural development 
process of islet formation, when late endocrine β cells forming from the ventral bud 
migrate within the pancreas to join the principal islet [185, 190]. 
 
2.3 Results 
Mig6 is conserved across species 
Genes and proteins of various animals may have various and nuanced functions 
within different organisms. We performed an amino acid sequence alignment comparing 
Mig6 among human, mouse, and zebrafish. NCBI Protein Blast was used to calculate 
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percent identity. Human and mouse Mig6 are 82% homologous, whereas human and 
zebrafish Mig6 are just 45% homologous. The function, structure, and mechanism of 
Mig6 as an EGFR inhibitor in human and mouse is described considerably [108, 109, 
181], so to determine functional similarities to zebrafish mig6, we analyzed the EGFR 
kinase binding domain sequence separately. It became evident that the EGFR kinase 
binding domain is extraordinarily conserved across all three species. The homology of 
the isolated region is 100% between human and mouse, and 89% between human and 
zebrafish (Figure 2-1 A-B). A sequence alignment of the EGFR protein determined 88% 
identity between human and mouse, and 63% identity between human and zebrafish, with 
high sequence homology in the Mig6 binding site (data not shown). With these data, we 
concluded that the Mig6-EGFR relationship and function in zebrafish was likely to be 
highly comparable to, if not identical to its relationship and function in human and 
mouse. 
mig6 is expressed in zebrafish 
To date, no studies have examined mig6 in zebrafish development. So, we report 
here the first expression data in this animal model. Temporal mig6 expression from 
whole-body zebrafish embryos revealed that mig6 was expressed at 2, 4, and 7 dpf, and 
of those times, it was most highly expressed at 4 dpf (Figure 2-2). Data from in situ 
hybridization of mig6 pinpoint both its temporal and spatial expression during 
organogenesis and pancreatogenesis. Expression of the genes insulin, fabp10, and mig6, 
as well as the sense control probe for mig6 was used to determine localized expression in 
the endoderm. By 3 dpf, mig6 was strongly expressed in the heart. At 3 dpf, mig6 
expression was observed in the liver and mig6 expression gradually increased in the liver 
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at 4 dpf and at 7 dpf. Mig6 expression was most robust at 4 and 7 dpf where it was clearly 
expressed in the heart, liver, and pancreas (Figure 2-3). Further analysis of the endoderm 
by in situ hybridization of the genes sox9b and mig6 revealed more specific expression 
patterns in the pancreas (Figure 2-4 A-D), but it appeared mig6 was expressed in a 
similar pattern to sox9b in the pancreas (Figure 2-4 E-L). 
mig6MO causes severe alterations in development  
To block production of Mig6 protein, we designed an ATG morpholino 
(mig6MO) targeting zebrafish mig6 at exon 2 and a splice morpholino (mig6MO2) 
targeting the junction of exon 3 and intron 3 (Figure 2-5 A). Injection of the ‘standard 
doses’ of either 2 or 4 ng of mig6MO was lethal to embryos at an early stage (data not 
shown). This observation is consistent with our assertion that mig6 is essential for 
development. We determined a dose range of 0.25 to 0.50 ng produces viable embryos 
for further study. Injection of mig6MO disturbed normal development in the zebrafish. 
Upon gross examination, mig6MO-injected embryos appeared stunted in growth and 
exhibited pericardial sac edema and an enlarged hindbrain ventricle (Figure 2-5 B) 
Insulin staining in the pancreas of the morpholino-injected embryos indicated that there 
was an altered pancreas phenotype in the mig6MO-injected embryos. We classified the 
various levels of morphological change into three categories: Normal, Class I, and Class 
II. Normal categorization was defined as a pancreas with tapered tail in combination with 
centered islet position (Figure 2-5 C). With this as a reference point, embryos with an 
uncentered islet (Figure 2-5 D) were classified as Class I, whereas embryos with the islet 
or partial islet protruding from the exocrine tissue (Figure 2-5 E) were classified as Class 
II. The separation of the islet and the exocrine tissue suggests that fusion of the dorsal 
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and ventral buds is impaired. The incidence of Class I and Class II embryos increased 
with increasing morpholino dose (Figure 2-5 F). 
mig6MO-injected embryos have a truncated exocrine pancreas and an elongated 
extrapancreatic duct 
During further assessment of the physical changes between control and injected 
embryos, we discovered that mig6MO-injected embryos had truncated pancreata as 
measured by the length of the exocrine tissue (Figure 2-6 A-C) through the medial line 
of the pancreas from pancreas head to tip of the pancreas tail. Initially, we hypothesized 
that knocking down mig6 would increase EGFR activity and result in growth of the 
pancreas. Interestingly and contrary to our expectations, the pancreas length decreased 
with increasing morpholino dose (Figure 2-6 D).  
Because mig6 is important to branching organs in the mouse, we were particularly 
interested in the development in the ducts. We stained control and mig6MO-injected 
embryos with gut secretory cell epitopes (2F11) to denote the ducts (Figure 2-7 A-C). In 
the mig6MO-injected embryos, the duct between the gall bladder and the pancreas, called 
the extrapancreatic duct (EPD), had a significant increase in length and area versus the 
control embryos (Figure 2-7 D-E).  
mig6 knock down results in fewer α and β cells 
The EPD gives rise to late endocrine cells that migrate and contribute to the 
expansion of the principal islet (Figure 1-5) [191-194], so we suspected that endocrine 
cell fate had also been altered with the change in EPD size. To analyze the impact of 
mig6 knock down to the pancreatic endocrine cells, we stained control and mig6MO-
injected embryos with insulin and glucagon and counted the number of α and β cells 
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(Figure 2-8 A). Whereas control embryos had an average of 28 β cells, mig6MO-injected 
embryos had 20 β cells on average (Figure 2-8 B). In addition, control embryos had 34 α 
cells, but mig6MO-injected embryos had just 21 α cells (Figure 2-8 C). 
mig6MO-injected embryos develop more β cells from the ventral bud 
Cells that develop from the ventral and dorsal buds were tracked by a label 
retaining cell (LRC) assay. The dorsal pancreas forms within 40 hpf and includes 
formation of the principal islet, whereas the ventral pancreas forms by 76 hpf and 
includes mostly acinar and exocrine pancreas cells [195]. The timing of this development, 
is consistent with cells in the ventral pancreas dividing at a higher rate than those in the 
dorsal pancreas, allowing the identification of cells that are dorsal bud- or ventral bud- 
derived. To this end, embryos were injected at the single cell stage with a fluorescent dye 
(H2B-RFP). Increased dilution of the dye is inversely related to intensity of fluorescence, 
so that more frequently dividing cells have more dilute dye and less intense red 
fluorescence. To evaluate derivations of β and α cells, control and mig6MO-injected 
embryos were stained at 4 dpf with insulin and glucagon. Insulin-positive cells with H2B 
dye present were designated LRC+ β cells (dorsal bud-derived); insulin-positive cells 
without H2B dye were designated LRC– β cells (ventral bud-derived). Glucagon-positive 
cells with and without dye were categorized similarly. In the mig6MO-injected embryos, 
significantly more β cells were derived from the ventral bud (Figure 2-9 A), with the 
dorsal bud trending to produce fewer β cells. Interestingly, fewer α cells were derived 
from the dorsal bud (Figure 2-9 B). 
gZ
!
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Figure 2-1. The EGFR kinase binding domain of Mig6 is conserved across species. (A) 
Amino acid sequence alignment of zebrafish, mouse, and human Mig6 protein by 
CLUSTAL Omega multiple sequence alignment software. (B) The EGFR kinase binding 
domain of Mig6 was isolated for sequence conservation and percent identity (% ID).  
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Figure 2-2. Dynamic expression of mig6 during pancreas development. mig6 expression 
was determined by qRT-PCR and normalized to the housekeeping gene β-actin. Data are 
presented as means ± SEM. 
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Figure 2-3. mig6 expression patterns in the heart, liver, and pancreas at various developmental stages. (A-L) Images of in situ 
hybridization document the temporal and spatial distribution of the genes insulin (A-C), fabp10 (D-F), and mig6 (G-L) in zebrafish 
embryos 3, 4, and 7 days post fertilization (dpf).  
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Figure 2-4. mig6 is expressed in the pancreatic ducts. (A-D) Magnified images of in situ hybridization identify the localized temporal 
and spatial distribution of the genes sox9b (A-B) and mig6 (C-D) in zebrafish embryos 3 dpf (E-H) Fluorescent in situ hybridization in 
Tg(Nkx2.2:GFP) 4 dpf embryos identified gene expression relative to the pancreatic ducts: insulin in the islet, sox9b in the pancreas, 
fabp10 in the liver, and expression of mig6. Vector Red was used to visualize expression. (I-L) Embryos from (E-H) were developed 
with BM Purple to confirm alkaline phosphatase activity.
��
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Figure 2-5. mig6 morpholino causes morphological changes in the exocrine pancreas. 
(A) Representative diagram of the mig6 gene with ATG and splice morpholino sequences 
and binding sites. (B) Representative images of control and mig6MO-injected embryos at 
4 dpf. The phenotypes observed were classified into groups by severity of deformity: 
Normal, Class I, and Class II. (C-E) Representative images of each classification 
demonstrate the distinct characteristics by which they were classified: Normal fish have a 
centered islet position within a normal exocrine pancreas. Embryos with an uncentered 
islet were classified a Class I, whereas fish with islets or β cells located outside the 
exocrine tissue were classified as Class II. Scale bar = 100µm. (F) Changes in 
phenotypic class with morpholino injection were quantified into percentages; n=23-54. 
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Figure 2-7. Knock down of mig6 results in an elongated extrapancreatic duct. (A-B) 
Representative images of the exocrine tissue marked by Tg(ptf1a:GFP), β cells marked 
by insulin (ins), and duct cells marked with 2F11. Scale bar = 100µm. (C) Graphic 
representation of images in panels A and B, labeling relevant aspects of pancreas 
anatomy: pancreas (P), principal islet (Pi), extrahepatic duct (EHD), extrapancreatic duct 
(EPD), and gall bladder (G) in zebrafish. (E) The length and (F) area of the EPD, was 
measured using ImageJ software; ****, p<0.0001, Student’s t-test. 
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Figure 2-9. More β cells are derived from the ventral bud in mig6MO-injected embryos. 
Using a label retaining cell (LRC) assay, we separated cells based on frequency of 
division by monitoring dilution of a dye, H2B-RFP. We term cells in the dorsal bud-
derived pancreas as LRC+ cells and those in the ventral bud-derived pancreas as LRC– 
cells. We counted the number of (A) insulin-positive LRC+ and LRC— cells and the 
number of (B) glucagon-positive LRC+ and LRC— cells in the control and mig6 
morpholino-injected embryos at 4 dpf; *, p<0.05,; **, p<0.01 Student’s t-test.  
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2.4 Preliminary Results  
β cell regeneration in mig6MO-injected embryos 
Previous studies in mice have uncovered that heterozygous whole-body knock out 
of Mig6 protects against β cell destruction and preserves β cell mass [105]. We 
hypothesized that mig6MO-injected embryos also have an improved response to stress 
stimuli. Utilizing the natural ability of zebrafish to regenerate their β cell mass, we treated 
control and mig6MO-injected Tg(ins:CFP-NTR) embryos with metronidazole (MTZ) to 
ablate β cells (Figure 2-10 A) by a proposed mechanism that generates ROS and 
cytotoxins that induce DNA damage (Figure 2-10 B). Embryos were allowed to recover 
for one day, then the regenerated β cells were quantified. There was no change in β cell 
regenerative capacity between control and mig6MO-injected embryos at 24 hours post 
ablation (hpa) (Figure 2-10 D). To determine the source of the regenerated β cells, the 
previously described LRC assay was used to separate dorsal bud-derived and ventral bud-
derived cells. There was no difference in the numbers of β cells that were ventral bud-
derived or dorsal bud-derived from control to mig6MO-injected embryos, although there 
was a difference from 0.25 ng to 0.50 ng mig6MO in β cells regenerating from the dorsal 
bud (Figure 2-10 E). 
Generation of mig6 mutants using CRISPR/Cas9 
We used CRISPR/Cas9 to create mig6 mutants and validate our mig6MO 
phenotype. To generate the CRISPR mutant, we designed a guide RNA (gRNA) target to 
exon 2 of the mig6 transcript. Injection of mig6 gRNA and Cas9 protein resulted in a 5-
bp deletion in exon 2 (Figure 2-11 A). This 5-bp deletion was predicted to lead to a 
frameshift mutation and a premature stop codon (Figure 2-11 B). Tg(ptf1a:GFP) 
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embryos injected with gRNA were visually screened to verify a similar pancreas 
phenotype by truncated pancreas. Those embryos were allowed to grow into adults and 
were genotyped by fin clip. Not all visually identified embryos had consistently mutated 
sequences. For example, “putants” in Figure 2-11 A were all visually categorized as 
mutants based on pancreas phenotype, yet only two of the four had the 5-bp deletion. F1 
generation zebrafish heterozygous for the mutation (confirmed by genotype) were 
crossed and the F2 generation offspring genotyped. Of the 18 random offspring taken for 
genotyping, 9 were wild-type (+/+) and 9 were heterozygous (+/-) for the mutation, but 
there were no homozygous mutants (Figure 2-11 C). Generation of a mig6 mutant line is 
yet to be confirmed. 
 
��
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Figure 2-10. There is no change in β cell regeneration between control and mig6MO-
injected embryos at 24 hpa. (A) Schematic of experimental design of targeted and 
specific β cell ablation using the transgenic line Tg(ins:CFP-NTR) expressing 
nitroreductase (NTR) in the β cells. (B) The reduction of NTR and its products’ reaction 
with metronidazole (MTZ) produces a cytotoxic environment in the NTR-expressing β 
cells, causing cross-linking of DNA strands (green) and inducing β cell death. (C) 
Representative images of islets from control and mig6MO-injected embryos treated with 
or without MTZ. Regenerating β cells were identified by antibody staining for insulin. 
(D) Total numbers of regenerating β cells (n=21-38) and (E) regenerating β cells 
separated into dorsal bud- and ventral bud-derived cells by LRC assay (n=18-34) were 
counted with ImageJ software. **, p<0.01, One-way ANOVA.  
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2.5 Discussion 
Pancreatic growth and development involve several stages, utilizing pancreatic 
progenitor cell populations to expand insulin-producing cells by β cell proliferation, 
transdifferentiation, and neogenesis. These progenitor cells represent a population of cells 
that can be targeted to endogenously increase β cell mass. We investigated the role of a 
novel zebrafish gene, mig6, in the development of the pancreas and the differentiation of 
progenitor cells. 
Alignment of amino acids of the human, mouse, and zebrafish Mig6 supports that 
the EGFR inhibitory function of mig6 in zebrafish is conserved. We demonstrate that 
mig6 is expressed in several different organs of the zebrafish, and although we focused 
on the pancreas and structures directly associated with the pancreas, we recognize that 
mig6 may have supplementary roles in the heart and liver that contribute to the pancreatic 
phenotype described here. It is plausible that the mig6MO-injected liver might exhibit a 
change in bile duct morphology or change in liver size. Similarly, we must draw attention 
to the pronounced expression of mig6 in the heart during development, and that the 
pancreas truncation in the mig6MO-injected embryos may be an effect of disrupted 
circulation-dependent pancreas growth. Circulation-dependent growth requires a healthy 
vascular network and has been proven necessary for liver development [196, 197]. 
Regardless, it is clear that the EPD augmentation is a primary result of a loss of mig6 in 
the EPD. Cell growth in the EPD stimulated local duct progenitor cells to prematurely 
differentiate, as evidenced by the restructured proportions of exocrine tissue, EPD, β 
cells, and α cells. 
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demonstrated that blocking Notch signaling results in premature differentiation of 
multipotent progenitor cells into endocrine cells [202, 203]. 
Lastly, our results do not exclude the possibility that mig6 does have an effect on 
regeneration after a β cell insult. However, because mig6 was knocked down for most of 
embryogenesis, its developmental phenotype may have concealed any changed 
regenerative capacity that could be observed if mig6 was conditionally knocked out after 
a pivotal period in pancreas formation. Such a model could uncover protective or 
degenerative mechanisms to progenitor cells after β cell stress. The role of mig6 in 
development is crucial to pancreas development and other organogenesis, but after the 
onset of diabetes, it could be a promising target of endocrine cell differentiation and 
restoration of β cell mass. 
 
2.6 Materials & Methods 
Animal maintenance 
Zebrafish were raised under standard laboratory conditions at 28°C. All zebrafish 
transgenic lines have been published previously [195]. Transgenic lines used are listed in 
Table 2-1. All lines were maintained and used in accordance with the “Guidelines for 
Use of Zebrafish in the NIH Intramural Research Program”. All animal procedures were 
conducted following OLAW guidelines, with the approval of the IU Institutional Animal 
Care and Use Committee. 
Genome editing 
The following antisense morpholino (MO) (Gene Tools, LLC) was injected into 
1-cell stage embryos: mig6 MO (targeting NM_001083570), 5’-
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ATTTCCTGGCCTGAATGCGAACCGA (0.25 ng and 0.50 ng), targeting the ATG site 
in exon 2. 100 pg H2BRFP mRNA was co-injected into zygotes along with mig6MO.  
We followed a published protocol for targeted CRISPR mutagenesis. We used 
Benchling online software to design mig6 sgRNA targeting 5’-GGCAGCCACTGGCAT-
AGCA in exon 2 (#1) and 5’-AGTTTCCGAATCTTGCTCC in exon 4 (#2). Mig6 
sgRNA #1 was injected in combination with Cas9 NLS (NEB) into 1-cell stage embryos 
of the Tg(ptf1a:GFP), and injected G0 larvae were raised to adulthood. Primers flanking 
each site were designed to amplify a 290 bp (#1) and a 249 bp (#2) PCR product and are 
listed in Table 2-2. Genomic DNA extraction was performed using REDExtract-N-Amp 
Tissue PCR Kit (Sigma-Aldrich).  Successful CRISPR mutagenesis was indicated by a 
change in PCR amplicon size, visualized by agarose gel electrophoresis. 
 
Table 2-1. Zebrafish transgenic lines 
Name Use Reference 
Tg(ins:CFP-NTR) β cell ablation Curado, S. et al., 2008 [172] 
Tg(ptf1a:GFP) exocrine and neural 
marker 
Anderson, R.M. et al., 2013 [204] 
Tg(nkx2.2:GFP) duct marker Ye, L et al., 2016 [182] 
Tg(gcga:GFP) α cell marker Pauls, S. et al., 2007 [205] 
Tg(ins:dsRed) β cell marker Anderson, R.M. et al., 2009 [206] 
 
Table 2-2. Primers for zebrafish CRISPR mutation determination 
Name Target gene Sequence (5'→3') 
gRNA #1 sense primer mig6 GGAGCATTTCCTGGCCTGAATG 
gRNA #1 antisense primer ACGCCAATCAGACACATTTGCT 
gRNA #2 sense primer CACCAAACCCCTTCCCCCAAT 
gRNA #2 antisense primer CTCGCCTTCTGTTGTTGTTGCT 
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β cell ablation and regeneration 
Zebrafish embryos were collected and cultured in standard conditions at 28°C in 
egg water supplemented with 4 mM 1-phenyl 2-thiourea (PTU) to inhibit melanophore 
formation. We analyzed regenerated β cells in the control and mig6MO-injected embryos 
using targeted conditional cell ablation using Tg(ins:CFP-NTR). 7.5mM metronidazole 
(MTZ) in egg water was added at 3 dpf and washed out at 4 dpf, allowing one day for 
recovery (See Figure 2-9). 
Label retaining cell assay 
100 pg H2BRFP mRNA was co-injected into zygotes. Dilution of the dye with 
every mitotic cell division allowed us to distinguish cells that were positive for the 
H2BRFP dye versus cell that were negative for the H2BRFP dye. Cells that differentiated 
early from the dorsal bud became quiescent sooner than those that undergo multiple 
round of mitosis from the ventral bud to make acinar and duct tissue. H2BRFP-positive 
and H2BRFP-negative β cells were counted as described in the following section.  
Immunofluorescence and in situ hybridization 
Whole mount immunofluorescent staining, and cell analysis were performed as 
previously described [207]. For immunofluorescence, the following antibodies were 
used: chicken α-GFP (Aves), guinea-pig α-insulin (Invitrogen), mouse α-glucagon 
(Sigma), mouse α-2F11 (Abcam), and rabbit α-dsRed (Takada). Alexa Fluor-conjugated 
antibodies (Life Technologies) were used for visualization, and DAPI or TO-PRO was 
used to visualize nuclei. Additional details are provided in Table 2-3.  
For whole mount in situ hybridization (ISH), antisense probes were transcribed 
from DNA templates that were generated by PCR from cDNA using primer sets that 
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amplify mig6, fabp10, insulin, or sox9b (Table 2-4). RNA with the T7 or T3 promotor 
was labeled with the DIG RNA Labeling Kit (Roche #11175025910). Gene expression 
was visualized with BM Purple (Roche #11442074001) or VectorRed (Vector Labs 
#SK5100) for fluorescent ISH (fISH).  
For Z-stack images and cell quantifications, embryos were imaged on LSM 700 
confocal microscope (Zeiss) and fluorescence and brightfield images were acquired on 
M205 FA whole mount epifluorescence dissecting microscope (Leica). All image 
processing and analysis was performed using ImageJ software. 
Statistical analysis 
All data are presented as means ± SD unless stated otherwise. The Student’s t-test 
(unpaired, two-tailed unless stated otherwise) or ANOVA was performed using 
GraphPad Prism software (La Jolla, CA, USA) to detect statistical differences. p < 0.05 
was considered statistically significant. 
 
Table 2-3. Antibodies used for zebrafish immunofluorescence staining 
 Name Species Dilution Company 
Primary anti-GFP chicken 1:500 or 
1000 
Aves Labs #GFP-1020 
anti-insulin guinea pig 1:100 Invitrogen #180067 
anti-glucagon mouse 1:100 Sigma #G2654 
anti-dsRed rabbit 1:500 Takada #632496 
anti-2F11 mouse 1:50 Abcam #ab71286 
anti-DIG AP sheep 1:4000 
(1:100 fISH) 
Roche #12486522 
Secondary AlexaFluor 405 mouse, 
rabbit 
1:250 Life Technologies 
#31553, #31556 
AlexaFluor 488 guinea pig, 
chicken 
1:250 Life Technologies 
#A1073, #A11039 
AlexaFluor 555 rabbit, 
mouse, 
guinea pig 
1:250 Life Technologies 
#A21428, #A31570, 
#A21435 
TO-PRO 647 - 1:500 Life Technologies #T3605 
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Table 2-4. Primers used for in situ hybridization 
Gene name Abbreviated 
name 
Strand Sequence (5'→3') 
mitogen-
inducible gene 6 
mig6 sense ATCTGACCGCATCAGTCCTC 
antisense 
+ T7 
gcatgcatgcattaatacgactcactatagggagaCGTC
GTTTTTCGTTTGCTTT 
antisense CGTCGTTTTTCGTTTGCTTT 
sense + 
T3 
gcataattaaccctcactaaagggagaATCTGACCG
CATCAGTCCTC 
insulin a insa sense GTCAATCGGGGGAGAAGAAG 
antisense 
+ T7 
GCtaatacgactcactataggTCACAAACATGA
TTGCCAGTG 
SRY (sex 
determining 
region Y)-box 9b 
sox9b sense ACACTCCGGTCAGTCTCAGG 
antisense 
+ T7 
taatacgactcactatagggTTGCTGTGGAGTG
CAAAAAC 
fatty acid binding 
protein 10 
fabp10 sense GGATCCGACGACTTTGTGTT 
antisense 
+ T7 
taatacgactcactataggGATGTTTGACCGGT
ACAGTGTTTATTA 
T3 or T7 promoters designated by lower case characters 
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CHAPTER 3. MECHANISTIC REGULATION OF MIG6 ACTIVITY 
 
3.1 Summary 
T1D is caused by autoimmune-mediated destruction of insulin-producing β cells. 
Following β cell injury, the pancreas attempts to launch a cellular repair and regenerative 
program, yet it fails to completely restore functional β cell mass. One component of the 
regenerative program is epidermal growth factor receptor (EGFR) signaling. Upon 
irreparable β cell damage, EGFR signaling is dampened, disrupting attempts to restore 
functional β cell mass and maintain normoglycemia. We previously demonstrated that the 
negative feedback inhibitor of EGFR, Mitogen-inducible gene 6 (Mig6), is induced by 
the pro-inflammatory cytokines central to the β cell destruction in T1D. We also 
established that pro-inflammatory cytokines suppress EGFR activation, and siRNA-
mediated suppression of Mig6 restores EGFR signaling.  
Recently, Mig6 was reported to be phosphorylated and activated by Src kinase. 
Interestingly, Src increases cell proliferation by activating receptor tyrosine kinases, such 
as EGFR, yet it is also implicated in the production of reactive oxygen species, including 
nitric oxide (NO). We hypothesized that pro-inflammatory cytokines activate Src kinase, 
and that along with NO, disrupt EGFR repair mechanisms through the induction and 
activation of Mig6. To test this hypothesis, we treated 832/13 cells independently with 
cytokines and high glucose and identified that these conditions increase the activation of 
Src.  We confirmed these results ex vivo in mouse islets. In the 832/13 cells, Src 
inactivation may protect EGFR signaling from the detrimental effects of cytokine 
exposure, but the role of nitric oxide (NO) was inconclusive. Our work suggests that Src 
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kinase may be involved in the progression to T1D by activating Mig6, and may be a 
component of Mig6 regulation that can be targeted to preserve β cell mass in T1D. 
 
3.2 Introduction 
In the progression to T1D, immune cells release pro-inflammatory cytokines into 
the injured β cell. Pro-inflammatory cytokines are well established as mediators of β cell 
damage [208, 209], a concept recapitulated in vitro [210]. Previous work has determined 
that among all the cytokines released during the immune response, only TNF-a, IL-1b, 
and IFN-g are required to produce the full inflammatory response in human islets [80]. 
The cytokines TNF-a and IL-1b stimulate their respective receptors and signal 
downstream to release NFκB from its inactivated complex with IκB; NFκB then 
translocates to the nucleus [211] to activate inducible NO synthase (iNOS) transcription, 
and subsequent NO production [212, 213]. NO is essential for β cell dysfunction and 
apoptosis [214]. Beyond activating NFκB signaling and producing NO, cytokines 
dampen EGFR activation in 832/13 cells [105], but the precise mechanism remains 
unknown. 
The mechanism(s) through which cytokines induce Mig6 expression, like EGFR 
inactivation, are also unclear. However, a recent report documented that activated Src 
“primes” Mig6 for EGFR inhibition (Figure 3-1) [113]. Src, a non-receptor tyrosine 
kinase of the Src family kinases, has been implicated in proliferation, survival, apoptosis 
and differentiation [118]. Src is activated by receptor tyrosine kinases, like EGFR, as well 
as other stimuli that are altered in diabetes pathogenesis, such as G-protein coupled 
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human and rodent islets [105]. To find similarities in physiological function, we treated 
isolated mouse islets with cytokines. In islets, 16 h cytokine treatment increased Src 
kinase phosphorylation (Figure 3-2 C). We hypothesized that Src activation increased 
Mig6 expression, but the mechanism is still unclear.  
Next, to assess the net and cumulative phosphorylation of Src, we inhibited 
phosphatase activity to promote Src activation under cytokine conditions. Cytokine 
pretreatment increased the cumulative phosphorylation of Src in both 832/13 cells 
(Figure 3-3 A, C) and isolated mouse islets (Figure 3-3 B, D).  
Src activation was not increased independently of EGFR, but Src inhibition may 
restore cytokine-impaired EGFR signaling 
EGFR has been shown to activate Src kinase in various cancer cell lines [215]. 
Thus, 832/13 cells treated with AG1478, a selective, irreversible EGFR inhibitor, was 
expected to decrease Src kinase activation. Instead, we observed unchanged Src 
activation (Figure 3-4 A, B). Surprisingly, when we treated cells with the Src inhibitor, 
PP1, EGFR signaling increased in cytokine-treated groups (Figure 3-4 C), suggesting a 
role for Src in cellular stress mechanisms, although this idea was not directly tested. 
Src inhibition activates Nos2, but NO decreases the net cumulative phosphorylation 
and activation of Src kinase 
Aside from its supposed Mig6 ‘priming’ role, we speculated that Src may also be 
important for gene expression, thus 832/13 cells were treated with several common Src 
kinase inhibitors. However, treatment with SU6656, PP1, and PP2 had no effect on Mig6 
expression (Figure 3-5 A). Src is activated by receptor tyrosine kinases, like EGFR, as 
well as other stimuli such as ROS [119-121]. We hypothesized that cytokines induce Src 
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activation by activating the NFκB signaling cascade to produce ROS such as nitric oxide 
(NO). Hence, we treated 832/13 cells with Src inhibitors to assess the role of Src in NO 
production. We report that with Src inhibition, Nos2 (mRNA precursor to iNOS) 
expression is increased (Figure 3-5 B) and pretreatment with PP1 allowed for increased 
cytokine-mediated Nos2 expression (Figure 3-5 C). In a reciprocal study, we evaluated 
the implications of increased NO production in the 832/13 cells. We treated cells with the 
NO donor DPTA/NO and quantified the change in Src activation. Interestingly, NO 
decreased the phosphorylation of Src (Figure 3-5 D), suggesting that in 832/13 cells, NO 
and Src may complement each other in regulatory mechanism. 
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Figure 3-5. Src inhibition increases Nos2 expression and NO donor decreases cumulative 
phosphorylation and activation of Src kinase. (A) 832/13 cells were treated with SU6656 
(10µM), PP1 (20µM), and PP2 (20µM) for 30 min. Relative expression normalized to 
Gapdh was determined by qRT-PCR; n=7. (B) 832/13 cells were treated with 10 or 
20µM PP1 for 30 minutes (n=3-5; *, p<0.05, One-way ANOVA) or (C) pre-treated with 
PP1 for 30 minutes, then exposed to 6h cytokines. Mig6, Nos2 and Gapdh mRNA levels 
were determined by qRT-PCR. n=4-5. (D) 832/13 cells were treated with 3h DPTA/NO 
then phosphatase activity was inhibited with 5min 50µM pV. n=2. *, p<0.05, 2-way 
ANOVA. 
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3.4 Preliminary Results  
Phosphorylation of Mig6 in cytokine-treated rat insulinoma cells 
Recently, Mig6 was discovered to be phosphorylated at tyrosine residues 394 and 
395 [113] and this portion of the Mig6 protein interacts with the EGFR kinase domain to 
inactivate downstream signaling [114]. To study the phosphorylation of Mig6, we 
commissioned a phospho-Mig6Y394, phospho-Mig6Y395 and phospho-Mig6Y394Y395 
antibody from 21st Century Biochemicals. Unfortunately, with this antibody, we could 
not detect tyrosine phosphorylation of Mig6 under cytokine, pV, or EGF- treatment (data 
not shown). Furthermore, mass spectrometry analysis indicated that Mig6 was 
phosphorylated on serine/threonine residues under cytokine treatment in 832/13 cells 
(data not shown, unpublished). 
β cell mass in Src whole-body knock out mice 
We determined β cell mass in Src whole-body knock out (Src KO) mouse 
pancreas sections by immunohistochemical staining of insulin. Preliminarily, there was 
no difference in β cell mass between wild type and Src knock out mice, but low statistical 
power may mask any trend of increased β cell mass (Figure 3-6). The Src KO mice 
exhibit severe bone fragility and would not be a good model of β cell stress. For this 
reason, we did not challenge the Src whole-body knock out mice to streptozotocin (STZ)-
induced β cell injury. We do speculate that a pancreas-specific knock out of Src would 
allow us to study the effect of Src on β cell mass after β cell injury. 
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Figure 3-6. Preliminarily, β cell mass in not changed in Src KO mice. Quantified islet 
area relative to total pancreatic area was calculated from immunohistochemical staining 
for insulin in pancreatic sections of control and Src KO mice, n = 3, each group. 
Student’s t-test, one-tailed. 
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3.5 Discussion 
Regulation of EGFR signaling via ancillary mechanisms like Mig6 circumvents 
concerns of targeting EGFR directly and the possibilities of tumor formation. To properly 
assess the potential of Mig6 as a therapeutic target, we must understand its endogenous 
regulatory mechanism, which is currently poorly defined. Src kinase was suggested to 
mediate phosphorylation of Mig6 at residues Y394 and Y395, but in this study, we were 
unable to confirm or refute this observation. We report that diabetogenic conditions (high 
glucose and cytokines) induce activation of Src kinase and increase the maximum 
phosphorylation threshold of Src kinase in both 832/13 cells and isolated mouse islets, 
implying that during the progression of diabetes and undiagnosed/unmanaged 
hyperglycemia, Src is activated. From our data, it appears Src is detrimental to EGFR 
signaling in 832/13 cells as Src inhibition resulted in increased p-EGFR in cytokine-
exposed conditions. Elsewhere, in high glucose conditions, Src inhibition protected 
against stress-induced EGFR transactivation and prevented nephrotic complications of 
diabetes [216]. Our current study did not assess transcriptional changes in EGFR, but we 
cannot dismiss the notion that the increased basal EGFR could be due to increased 
transcription of EGFR and higher numbers of receptors expressed on the cell surface, 
rather than increased EGFR activation per se. To assess the role of Src in cytokine-
mediated EGFR inhibition, we would need to evaluate Src inhibition on EGFR ligand-
dependent activation.  
Analysis of Mig6 phosphorylation was inconclusive, and our studies may have 
been limited by the assumption that it was phosphorylated on tyrosine residues in the 
832/13 cell line, as in other cell types. For instance, checkpoint kinase 1 (Chk1) was 
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shown to phosphorylate Mig6 at serine 251 in human cell lines [111]. Although it is 
unknown how phosphorylation of serine 251 control aspects of Mig6 function, we 
wonder if Mig6 may function in concert with serine/threonine kinases (STKs), which 
have been associated with anti-proliferative/pro-apoptotic mechanisms and cell cycle 
regulation [217, 218]. We did assess transcriptional regulation of Mig6 by Src kinase by 
inhibiting Src, but there was no significant change in Mig6 expression. Src inhibition did 
increase iNOS expression, and we observed that Src inhibition tended to allow for 
increased cytokine-induced NO production. However, treatment with a NO donor 
decreased the activation of Src kinase (Y416). Src may serve as a buffer for cytokine-
mediated NO production and cytokine induce it as a self-check mechanism.  
Most of the studies reported here were conducted with Src inhibitors, but perhaps 
the expression of constitutively active Src kinase would directly inform a role in Mig6 
expression or protein. In addition, what this study did not elucidate was the effect of 
EGFR inhibition on modulation of Src kinase on other phosphorylation sites, such as on 
Y527, which would aide in Src kinase activation.  The activation of Src is facilitated by 
phosphorylation of Y416 as well as dephosphorylation on Y527 [219].  
From these data, we can conclude that Src kinase in activated under diabetogenic 
conditions, such as high glucose and cytokines, and its activation facilitates cytokine-
mediated NO production. Further studies would reveal the impact of increased activated 
Src kinase on cytokine-mediated EGFR activation or possible transactivation. In addition, 
an antibody that could detect Mig6 phosphorylation on Y395/Y394 would delineate 
whether or not Src activation increases p-Mig6. Nonetheless, our study contributes data 
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of mitogenic signaling control mechanisms in the 832/13 cells, that may be useful as the 
regulatory mechanism of Mig6 becomes more apparent. 
 
3.6 Materials & Methods 
Animal maintenance 
All animals were maintained and used in accordance with protocols approved by 
the Indiana University School of Medicine Institutional Animal Care and Use Committee, 
following the Guide for the care and use of laboratory animals, Eighth edition (2011). 
Mice were maintained in a standard 12-hour light-dark cycle and provided unrestricted 
access to water and a standard rodent chow. Wild type C57Bl/6J mice were used for islet 
experiments. Src knock out mouse tissue was a gift from Dr. Fred Pavalko (Indiana 
University). Extract-N-Amp Tissue PCR kit (Sigma-Aldrich, St Louis, MO, USA) was 
used for DNA extraction.  
Histological studies 
Immunostaining of pancreatic sections was performed as previously described 
[105]. β cell mass was determined by staining for insulin (Invitrogen #180067) and 
calculating insulin-positive area relative to total pancreas area.  
Islet experiments 
Mouse islets were isolated and cultured as previously described [106, 220] for 
protein and mRNA analysis. Groups of 50-100 islets from wild type mice were pretreated 
with a pro-inflammatory mouse cytokine cocktail (1000 U/ml TNF-a, 50 U/ml IL-1b, 
and 1000 U/ml IFN-g; Prospec, East Brunswick, NJ) and treated with 50 µM pervanadate 
(pV) for 5 min in 11.1 mM glucose RPMI. 
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Cell experiments  
INS-1-derived 832/13 rat insulinoma cells were cultured as previously described 
[221]. A starvation medium (RPMI 1640 containing 2.5 mmol/l glucose and 0.1% BSA) 
was used for EGF stimulation experiments. For cytokine plus pV experiments, 832/13 
cells were pretreated with a pro-inflammatory rat cytokine ‘cocktail’ (1000 U/ml TNF-a, 
50U/ml IL-1b, and 1000 U/ml IFN-g; Prospec, East Brunswick, NJ) for 16 hours, starved 
for 2 hours and treated with 50 µM pV (R&D Systems, Minneapolis, MN, USA) for 5 
min. For nitic oxide experiments, 832/13 cells were treated with 200 µM DPTA/NO 
(Cayman Chemical, Ann Arbor, MI, USA) for 3 hours. For EGFR inhibition 
experiments, AG1478 was added at 20 µM. The Src inhibitors used were SU6656 (10 
µM), PP1 (10 and 20 µM), and PP2 (20 µM) for 30 min. 
Immunoblot analysis 
Immunoblot analysis was performed as previously described [106]. 
Phosphorylated protein levels were normalized to total protein levels, and total (i.e. non-
phosphorylated) protein levels were normalized to tubulin or GAPDH protein levels. 
Antibodies are listed in Table 3-1.  
Quantitative RT-PCR analysis  
RNA from 832/13 cells, and mouse, rat, and human islets was isolated using 
RNeasy Mini or Micro kits (Qiagen, Valencia, CA, USA). Reverse transcription was 
performed using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems, 
Foster City, CA, USA). TaqMan assays (Applied Biosystems) were used to obtain CT 
values and the ΔΔCT method was used to calculate the relative quantities of mig6, gapdh, 
or NOS2 mRNA. Primer sequences were described previously [222]. PCR reactions were 
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performed in triplicate for each sample from at least three independent experiments and 
normalized to Gapdh mRNA levels.  
 
Table 3-1. Antibodies used for immunoblotting 
Name Vendor, catalog number Dilution Solvent 
anti-phospho-EGFR 
(Y1068) 
Cell Signaling, #3777 1:1000 Nacalai USA 
Signal Enhancer 
Hakari 250 
anti-EGFR Sigma-Aldrich, #E3138 1:1000 Nacalai USA 
Signal Enhancer 
Hakari 250 
anti-γ-tubulin Sigma-Aldrich, #T6557 1:2500 PVP 
anti-Mig6 Santa Cruz, #D-1 
21st Century Biosciences,  
1:250 
1:200 
PVP 
PVP 
Anti-Src kinase Cell Signaling 1:1000 PVP 
Anti-phospho-
Src(Y416) 
Cell Signaling 1:1000 PVP 
Anti-actin MP Biomedicals #691002 1:2500 PVP 
 
Statistical analysis  
All data are presented as means ± SEM. Protein and mRNA data were normalized 
to control conditions and presented as relative expression. The Student’s t-test (unpaired, 
two-tailed unless stated otherwise) or ANOVA (with Bonferroni post hoc tests) were 
performed using GraphPad Prism software (La Jolla, CA, USA) to detect statistical 
differences. p < 0.05 was considered statistically significant.  
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CHAPTER 4. MIG6 ACCELERATES THE PROGRESSION TO DIABETES BY 
BLOCKING ENDOGENOUS EGFR REGENERATIVE MECHANISMS 
 
4.1 Summary 
Type 1 Diabetes (T1D) is caused by autoimmune-mediated β cell destruction. 
Following β cell injury, the pancreas attempts to launch a cellular repair and regenerate 
program, yet it fails to completely restore functional β cell mass. One component of the 
regenerative program is epidermal growth factor receptor (EGFR) signaling. However, 
upon irreparable β cell damage, EGFR signaling is dampened, disrupting attempts to 
restore functional β cell mass and maintain normoglycemia. We have previously 
demonstrated that the negative feedback inhibitor of EGFR, Mitogen-inducible gene 6 
(Mig6), is induced by the pro-inflammatory cytokines central to the autoimmune-
mediated β cell destruction. We also established that pro-inflammatory cytokines 
suppress EGFR activation, and siRNA-mediated suppression of Mig6 restores EGFR 
signaling. Thus, we hypothesized that pro-inflammatory cytokines induce nitric oxide 
production and that in turn induced Mig6, disrupting EGFR repair mechanisms. We 
determined that NO induces Mig6, attenuating EGFR signaling, and NO synthase 
inhibition blocks the cytokine-mediated induction of Mig6, thereby restoring cytokine-
impaired EGFR signaling. To that end, we treated mice lacking pancreatic Mig6 and 
wild-type mice with a streptozotocin (STZ) to induce β cell death and diabetes in a way 
that mimics the onset and progression of T1D. Whereas STZ-treated wild-type mice 
became hyperglycemic and had reduced β cell mass, STZ-treated Mig6 PKO mice 
remained euglycemic and glucose tolerant due to preserved β cell mass. β cell 
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proliferation seems to be involved in this preservation. Our work suggests that Mig6 is a 
promising target to preserve β cell mass before overt T1D. 
 
4.2 Introduction 
Type 1 Diabetes (T1D) is a progressive disease characterized by autoimmune-
mediated destruction of the pancreatic insulin-secreting β cells.  Multiple human and 
animal studies support the concept that progression to overt diabetes is accompanied by 
both β cell dysfunction and destruction [100, 105]. β cell destruction in T1D can occur 
through a series of immunological attacks and recoveries, termed “relapsing-remitting” 
[33]: a process which gradually reduces functional β cell mass until symptoms of 
hyperglycemia are noticed and diabetes is diagnosed. During the progression to diabetes, 
immune cells such as macrophages are recruited and promote inflammation by releasing 
pro-inflammatory cytokines into the islet [10], which activates stress activated kinases, as 
well as NFκB signaling and iNOS expression [214, 223]. Such signaling events lead to 
increased endoplasmic reticulum (ER) stress, increased apoptosis, and decreased β cell 
function and regeneration, all of which culminates in the loss of functional β cell mass 
and diabetes.  
The relapsing-remitting features of diabetes extends past clinical diagnosis to the 
‘honeymoon phase’, where residual bet cell mass provides endogenous insulin to support 
exogenously delivered insulin by the patient. The honeymoon phase provides an 
opportune time for therapeutic intervention; in fact, clinical trials for delivering 
immunomodulatory agents in this window are underway [224]. These therapeutic 
strategies, that target the immune response but neglect intrinsic cellular pathologies 
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within the islet, have resulted in immunological approaches that are largely ineffective in 
the long term. In contrast, cellular therapies can promote β cell proliferation, survival and 
recovery, essentially restoring β cell mass [41]. Nevertheless, translating pre-clinical 
successes to patients with T1D has been challenging. For example, administration of 
epidermal growth receptor (EGF) and gastrin in combination increases β cell mass and 
reverses hyperglycemia in NOD mice [99], but this approach has yet to translate into a 
viable treatment for humans.  
The EGF receptor (EGFR) cascade has proven to be crucial in the regulation of 
pancreatic β cell mass as it regulates cell growth, proliferation, survival, and 
differentiation [225]. Mice lacking EGFR acquire diabetes within two weeks of birth and 
have impaired islet development [95], and mice expressing constitutively active EGFR 
have increased β cell mass [97]. EGFR signaling activates downstream effectors such as 
Akt, which promotes cell survival, and ERK, which increases cell proliferation [106]. 
Additionally, in some β cell regeneration studies, expression of EGF ligands increases 
[93], suggesting that this pathway is involved in an intrinsic β cell regeneration and repair 
program.  
However, endogenous feedback mechanisms restrain EGFR activation, thereby 
preventing the full regenerative actions of EGFR signaling. One such mechanism is 
Mig6, a cellular response protein and feedback inhibitor of EGFR that has been 
characterized as a molecular “brake” for β cell proliferation [107, 226] and survival [105, 
106]. Activation of EGFR signaling induces Mig6 in a classic feedback mechanism, 
suppressing kinase activity and initiating receptor endocytosis and degradation [227]. 
Mig6 haploinsufficient mice are protected against chemically-induced diabetes [105], 
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suggesting that Mig6 antagonizes β cell mass. In addition, increasing Mig6 expression 
with a recombinant adenoviral compromises β cell integrity and islet function [105]. 
Thus, Mig6 expression levels can modulate functional β cell mass. 
Not only is Mig6 induced during EGFR activation, but it is also activated by other 
factors, such as the pro-inflammatory cytokines from the T1D milieu [105]. Pro-
inflammatory cytokines are well established mediators of β cell damage [208, 228], and 
this concept has been verified in vitro [210]. Previous work has determined that of all the 
cytokines released during the immune response, only TNF-α, IL-1β, and IFN-γ are 
required to produce the full inflammatory response [80]. TNF-α and IL-1β stimulate their 
respective receptors and initiate a downstream signaling cascade that results in 
transcription of inducible NO synthase (iNOS) and consequent NO production [211-213]. 
NO is essential for β cell dysfunction and apoptosis [214]. Besides activation of the 
NFκB pathway and NO production, we have demonstrated that cytokines reduce the 
EGFR signaling, which can be rescued by Mig6 suppression.  We aim to address the role 
of NO in cytokine-mediated EGFR suppression as well as in vivo β cell regenerative 
effects of Mig6 pancreas-specific knock out. 
 
4.3 Results  
NO is detrimental to EGFR signaling 
Previous studies in our lab have reported that cytokines dampen EGFR 
phosphorylation and that Mig6 suppression by siRNA rescues this inhibition in 832/13 
cells [105]. Given our findings on the relationship between NO and Mig6, we 
investigated the direct role of NO on EGFR signaling. As an extension of our previous 
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work [105], we discovered that NO alone dampens EGFR phosphorylation (Figure 4-1 
A-B). Yet, signaling of extracellular signal-regulated kinase 1 and 2 (ERK1/2), a 
downstream messenger of EGFR, remains intact following treatment with NO donor, 
suggesting that this downstream signaling arm persists (Figure 4-1 C).  
To further assess the role of NO in EGFR signaling, we treated 832/13 cells with 
the iNOS inhibitor, L-NMMA (Figure 4-2 A) and observed that cytokines dampen 
EGFR signaling as expected, but that a combinatory treatment of cytokines and L-
NMMA caused an overwhelming restoration of EGFR signaling (Figure 4-2 B). We 
confirmed NO production with cytokine and NO donor/inhibitor treatments by measuring 
nitrite production (Figure 4-1 D, 4-2 D). 
Cytokine-induced Mig6 expression requires NO 
It is widely accepted that cytokines, the mediators of immune-cell damage, are 
involved in the progression to T1D [229]. Pro-inflammatory cytokines induce Mig6 
expression in both human islets and 832/13 cells [105]. Here, we verify that cytokines 
increase Mig6 expression in the 832/13 cell line (Figure 4-3 A), and demonstrated that 
cytokine-induced Mig6 expression requires cytokine-mediated NO (Figure 4-2). 
Interestingly, NO alone was not sufficient to increase Mig6 expression in either a dose- 
or time-dependent manner (Figure 4-3 B-C), suggesting NO functions in a permissive 
manner to induce Mig6 with activated cytokine signaling. This would also imply that 
dampening of EGFR signaling by NO donor is independent of Mig6 feedback inhibition. 
Taken together, these data indicate that NO is detrimental to EGFR signaling. By 
contrast, at the transcriptional level, NO itself does not induce Mig6. We maintained our 
impression that Mig6 activates repair mechanisms through the EGFR pathway. So, we 
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used an in vivo transgenic mouse to assess how the loss of Mig6 affects repair 
mechanisms downstream of EGFR signaling.  
Mig6 PKO mice have normal β cell mass and islet structure 
As previously reported, whole-body Mig6 heterozygous knock out mice were 
protected from streptozotocin (STZ)-induced glucose intolerance, with no change in 
insulin sensitivity [105]. Yet, this mouse model was not pancreas-specific, and the 
corrections in glucose tolerance waned at 20-days post STZ injection. To directly assess 
Mig6’s actions in the pancreas, we developed a pancreas-specific Mig6 knock out mouse 
(Mig6 PKO) by breeding a Pdx-Cre mouse model with Mig6flox/flox mice, developed as 
previously described [230].  This knock out resulted in a 50% knock down of Mig6 
protein and mRNA in the pancreatic islet (Figure 4-4 A-C). Control and Mig6 PKO mice 
have no difference in β cell mass (Figure 4-4 D), quantified from immunohistochemical 
(IHC) staining of insulin as insulin-positive area relative to pancreas area. We also 
observed no difference in islet morphology (Figure 4-4 E). 
Mig6 PKO mice have lower fasting blood glucose and increased glucose tolerance 
after STZ treatment compared to control mice 
Multiple low doses (MLD) of STZ causes hyperglycemia by damaging DNA in 
the β cell and by inducing inflammatory mediators that infiltrate the islet, promoting β 
cell dysfunction and death [231, 232]. MLD-STZ treatment is an experimental model that 
mimics features of the autoimmune-mediated β cell destruction observed during the 
progression to human T1D. We subjected Mig6 PKO and control mice to MLD-STZ, 
then challenged them by performing glucose tolerance tests at 3-days and 20-days post 
STZ injection. 3-days post STZ treatment, whereas control littermates developed fasting 
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hyperglycemia, Mig6 PKO mice maintained fasting blood glucose comparable to 
pretreatment blood glucose concentrations (Figure 4-5 A-B). Mig6 PKO mice 
maintained this glycemic control to at least 20-days post STZ treatment. In addition, 
when given a glucose challenge, Mig6 PKO mice treated with STZ remained glucose 
tolerant compared to their littermate controls at 3-days post STZ treatment and this 
perpetuated 20-days post STZ (Figure 4-5 C-F). 
Mig6 PKO mice have preserved β cell mass after STZ treatment 
Prolonged fasting normoglycemia and glucose tolerance suggests Mig6 PKO 
mice are protected against STZ injury. We again performed IHC staining for insulin on 
20-days post STZ sections and normalized to pancreas area. Β cell mass was significantly 
higher in STZ-treated MIg6 PKO mice compared to STZ-treated control mice and was 
not different to saline treated mice (Figure 4-6 A-B). At 3- and 20-days post STZ 
treatment, we counted the total number of established islets, omitting groups of less than 
10 β cells. Because there was no change in islet architecture, we suspected that β cell 
proliferation played a role in the observed protection.  
Ki67 and phospho-histone H3 (pHH3) are markers of cells in the cell cycle. We 
counted the number of Ki67-positive or pHH3-positve β cells in pancreas sections of 
control or Mig6 PKO mice. Following STZ injury, Mig6 PKO mice have a higher 
number of proliferating β cells in the early stages of recovery, demonstrated an increased 
proportion of Ki67-positive cells to total islet area (Figure 4-7 A), as well as a higher 
absolute number of Ki67-positive cells (Figure 4-7 C). Although the increased number 
of Ki67-positive cells persisted at 20-days post-STZ, the relative proliferative effect 
ceased after 20 days of recovery (Figure 4-7 E). There were no changes in pHH3-
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positive β cells at 3-days (Figure 4-7 B, D) or 20-days post-STZ treatment (Figure 4-7 
F, H). This depression in proliferative response late after β cell insult may contribute to 
the waning protection against hyperglycemia at 20 days recovery (Figure 4-5). 
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Figure 4-3. Cytokine-induced NO is necessary for Mig6 expression, but NO alone is 
insufficient. (A) 832/13 cells were treated with cytokines (TNFα, IL-1β, IFN-γ) and/or 
the iNOS inhibitor, L-NMMA for 24 h or (B,C) DPTA/NO at 100-400µM at times 
ranging from 30m to 4h. Cytokine effectiveness was confirmed by measuring Nos2 
mRNA (data not shown).  Mig6 and Gapdh mRNA levels were determined by qRT-PCR. 
n = 3-6; *, p<0.05 vs. non-treated control, Student’s t-test; #, p<0.001 vs. cytokine-
treated, One-way ANOVA. 
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Figure 4-4. Pancreatic Mig6 knock out (Mig6 PKO) mice have decreased Mig6 protein 
levels and decreased mRNA expression. (A) Western blot representative image for graph 
(B) where islets were collected from control and Mig6 PKO mice and lysates collected 
for protein analysis. n=6-8; **, p<0.01 Student’s t-test. Islets were isolated and cDNA 
was prepared by RT-PCR. (C) Mig6 expression was determined by qPCR and normalized 
to Gapdh relative to a control sample. n=6-10; ***, p<0.001 Student’s t-test. (D) 
Quantified islet area relative to total pancreatic area from saline-injected mice of both 
genotypes. n=4-6. (E) Images of immunofluorescent staining of insulin (red) and the 
glucagon (green), from an untreated control vs. Mig6 PKO mouse islet. 
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Figure 4-5. Mig6 PKO mice have a lower fasting blood glucose after STZ treatment, and 
have a slightly higher glucose tolerance than wild-type littermates. (A) 6-hour fasting 
blood glucose (FBG) of both genotypes before and after treatment. n = 3 (STZ CTRL) 
n=16-24 (other groups); ****, p<0.0001, 2-way ANOVA vs control. (B) 6-hour FBG 
over time post-STZ treatment, showing that Mig6 PKO mice maintain FBG up to 20-days 
post STZ injection n = 3 (STZ CTRL) n=16-24 (other groups); ***, p<0.001; ****, 
p<0.0001 in 2-way ANOVA vs control pretreatment.  (C) 10-week old Mig6 PKO and 
control mice received daily injections of 35 mg/kg body weight of streptozotocin (STZ) 
or volumetric equivalent of isotonic saline over 5 consecutive days. Intraperitoneal 
glucose tolerance test (GTT) of Mig6 PKO and control mice 3 days and (D) 20 days post-
STZ or post-saline injection. *, p<0.05, **, p<0.01, ***, p<0.001, ****, p<0.0001 in 
multiple t-test vs Mig6PKO-STZ. (E) Calculated area under the GTT curve at 3-days and 
(F) 20-days post STZ injection.  
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Figure 4-6. Mig6 PKO mice have preserved β cell mass and preserved islet morphology. (A) Quantified islet area relative to total 
pancreatic area after STZ treatment (dotted line represents saline-injected control mice) calculated from (B) immunohistochemical 
staining for insulin in pancreatic sections of control and Mig6 PKO mice 20 days post-STZ treatment, n = 4-6; **, p<0.01 vs control 
Student’s t-test. Immunofluorescent staining in pancreas sections of control and Mig6 PKO mice was employed to characterize islet 
morphology at 3- (C,E) and 20-days (G,I) post STZ injection and to calculate (C,G) total number of islets n=3-5; **, p<0.01, 
Student’s t-test, one-tailed, (E,I) and islets containing more than 10 β cells. n=3; *, p<0.05 Student’s t-test, one-tailed. 
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4.4 Discussion 
EGFR signaling has been a focus of studies aiming to restore β cell mass in 
patients with diabetes. Past studies have illustrated the potential benefits of cellular 
therapies: combinatorial administration of EGF and gastrin [99] rescues hyperglycemia, 
and constitutively active EGFR have increased β cell mass [97]. In this study, we 
examined how pro-inflammatory cytokines, widely accepted to participate in the immune 
response during T1D, restrain EGFR signaling. Cytokines induce iNOS expression and 
NO production, and we further demonstrated that cytokine-induced NO is necessary for 
Mig6 expression. We also present evidence that EGFR signaling is dampened by NO, 
from cytokines or an NO donor itself. Given downstream ERK signaling was sometimes 
not changed in parallel to EGFR signaling, we redirect to reports that NO can trigger 
different effector mechanisms in the immune response depending on its concentration 
and ligand binding [233-236]. Therefore, we recognize that NO may have ancillary 
positive or negative effects on various tissues and cascades at varying concentrations. In 
832/13 cells treated with NO donor, whereas EGFR signaling was dampened, ERK was 
not activated, suggesting that there are compensatory or secondary mediators of 
proliferation and survival in the β cell. Given the permissive role of NO to induce Mig6, 
there may be outcomes that are masked by a too broad use or saturated concentration of 
NO. Because the variable consequences and benefits of NO, it will be interesting to 
determine whether NO in variable concentrations or sources affects Mig6 expression and 
EGFR signaling. 
We further refined our previous mouse model to a pancreas-specific knock out of 
Mig6 and we observed a comparable phenotype to our Mig6 haploinsufficient mouse 
 95 
model. The increased glucose tolerance in the Mig6 PKO was significant but not as 
striking as the phenotype of our previous model. We include a measure of Mig6 knock 
down efficiency, which was about 50% knocked down. It is possible that a more 
complete knock down of Mig6 would result in an even more normal glucose tolerance 
after STZ β cell injury. Most notably, Mig6 PKO mice have normal fasting blood glucose 
which persists from 3- to 20- days post STZ treatment, with a more improved glucose 
tolerance at 3-days post STZ treatment, and this tolerance beginning to deteriorate 
approaching 20-days post injury. Mig6 PKO mice also have an improved β cell mass 
recovery after 20 days compared to their wildtype littermate control mice after STZ 
injury. Together, these data suggest that Mig6 accelerates the progression to diabetes 
after an immunological attack on the β cells. 
Through histological analysis of pancreatic sections, we report that Mig6 PKO 
mice had increased numbers of Ki67-positive cells. Our previous report in the Mig6 
haploinsufficient mouse model concluded that there is no difference in STZ-stimulated β 
cells that have entered into the M phase of the cell cycle. Here we report a more 
encompassing marker of proliferation, Ki67, which identifies all cells in any stage of the 
cell cycle. Because it is suggested that duct-associated islets and single extra-islet β cells 
indicate ongoing duct-to-islet neogenesis [237], we also noted the number of islets 
(including singlets) that were associated with a duct. Numbers of duct-associated islets 
were not different between the control and Mig6 PKO mice (data not shown), indicating 
an intrinsic change in cell fate. We defined the mechanism of β cell mass preservation as 
exploitation of β cell proliferation. The involvement and contribution of other means of β 
cell restoration, such as β cell transdifferentiation and neogenesis, which in other 
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transgenic models have been shown to potentially increase the reservoir of new β cells 
[195, 238], have yet to be published in the context of Mig6 knock down. 
In summary, our data demonstrated that NO is detrimental to EGFR activation 
and phosphorylation, and is required for cytokine-mediated Mig6 expression. Yet NO 
alone does not induce Mig6. Like in our previous Mig6 haploinsufficient mouse model, 
when knocked down in the pancreas, Mig6 protects mice from chemically-induced 
hyperglycemia by preventing loss of β cell mass. This study highlights the pitfalls of 
treatments solely focused on the immunological response, as pathological stimuli can 
detrimentally impact mitogenic signaling and therefore EGFR regenerative mechanisms 
via Mig6 feedback inhibition. Mig6 presents a promising cellular therapeutic alternative 
that, when used to target β cell recovery programs, may prevent or reverse the 
progression to diabetes. 
 
4.5 Materials & Methods 
Animals and treatments 
All animals were maintained and used in accordance with protocols approved by 
the Indiana University School of Medicine Institutional Animal Care and Use Committee, 
following the Guide for the care and use of laboratory animals, Eighth edition (2011). 
Mice were maintained in a standard 12-hour light-dark cycle and provided unrestricted 
access to water and a standard rodent chow. Tg(Pdx1-cre) mice (Jackson Laboratory 
#014647) were bred with Mig6flox/flox or Mig6flox/+ [230] on a C57Bl/6J background. The 
following primer sequences (Integrated DNA Technologies) were used to detect Pdx1-
Cre and Mig6flox: Pdx-forward = 5’-CTGGACTACATCTTGAGTTGC, Pdx-reverse = 5’-
 97 
GGTGTACGGTCAGTAAA-TTTG, Mig6flox-forward = 5’-
GGTCAGGGCTGTGCAGTCCGTAGA, Mig6Neo-reverse = 5’-
CGATACCCCACCGAGACC, and Mig6flox-reverse = 5’-CTTCCCAAATCTAAC-
ACCCGACAC. Extract-N-Amp Tissue PCR kit (Sigma-Aldrich, St Louis, MO, USA) 
was used for DNA extraction.  
8 to 10-week old male mice of the genotypes Mig6flox/flox/Cre+ (Mig6 pancreatic 
knock out), Mig6flox/+/Cre-, and Mig6flox/flox/Cre- (controls) were intraperitoneally injected 
with streptozotocin (STZ, 35mg/kg body weight; Sigma-Aldrich, St Louis, MO, USA) 
for 5 consecutive days as performed previously [105]. A group of control animals was 
injected in the same manner with vehicle (saline). 
Metabolic tests 
For glucose tolerance testing (GTT), 1.5 g/kg body weight D-glucose (Sigma-
Aldrich) was intraperitoneally injected into 6-h-fasted control or STZ-treated mice. Blood 
was sampled from a tail vein at the indicated time points, and blood glucose was 
measured using an AlphaTrak glucometer (Abbott Laboratories, Abbott Park, IL, USA). 
Area under the curve (AUC) was calculated as the area under each point in the graph, 
averaged over the time between points, adjusting (subtracting) the initial fasting BG 
contribution. 
Immunohistochemical and immunofluorescence staining 
Immunostaining of pancreatic sections was performed as previously described 
[105]. Antibodies are listed in Table 4-1. 
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Table 4-1. Antibodies used for immunofluorescence staining 
Name Vendor, catalog number Dilution 
Anti-insulin Santa Cruz, #H-86 
Invitrogen, #180067 
1:250 
1:250 
Anti-phospho histone H3 Millipore, #06-570 1:200 
Anti-Ki67 Abcam, #15580 1:900 
 
Islet experiments 
Mouse islets were isolated and cultured as previously described [106, 220] for 
protein and mRNA analysis.  
Cell experiments  
INS-1-derived 832/13 rat insulinoma cells were cultured as previously described 
[221]. A starvation medium (RPMI 1640 containing 2.5 mmol/l glucose and 0.1% BSA) 
was used for EGF stimulation experiments. For cytokine/EGF stimulation experiments, 
832/13 cells were pretreated with a pro-inflammatory rat cytokine ‘cocktail’ (1000 U/ml 
TNFa, 50 U/ml IL-1b, and 1000 U/ml IFN-g; Prospec, East Brunswick, NJ) for 16 hours, 
starved for 2 hours and treated with 10 ng/ml rat recombinant EGF (R&D Systems, 
Minneapolis, MN, USA) for 5 min. For nitic oxide experiments, 832/13 cells were treated 
with L-NMMA (MilliporeSigma, St Louis, MO, USA) for 16 h, or DPTA/NO (Cayman 
Chemical, Ann Arbor, MI, USA) for 4 hours. 
Immunoblot analysis 
Immunoblot analysis was performed as previously described [106]. 
Phosphorylated protein levels were normalized to total protein levels, and total (i.e. non-
phosphorylated) protein levels were normalized to tubulin or GAPDH protein levels. 
Antibodies are listed in Table 4-2. 
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Table 4-2. Antibodies used for immunoblotting 
Name Vendor, catalog number Dilution Solvent 
anti-phospho-EGFR 
(Y1068) 
Cell Signaling, #3777 1:1000 Nacalai USA 
Signal Enhancer 
Hakari 250 
anti-EGFR Sigma-Aldrich, #E3138 1:1000 Nacalai USA 
Signal Enhancer 
Hakari 250 
anti-phospho-ERK1/2 
(p42/44) 
Cell Signaling, #4370 1:1000 PVP 
anti-ERK1/2 Cell Signaling, #4696 1:1000 PVP 
anti-γ-tubulin Sigma-Aldrich, #T6557 1:2500 PVP 
anti-Mig6 Santa Cruz, #D-1 
21st Century Biosciences 
1:250 
1:200 
PVP 
PVP 
 
Quantitative RT-PCR analysis  
RNA from 832/13 cells, and mouse, rat, and human islets was isolated using 
RNeasy Mini or Micro kits (Qiagen, Valencia, CA, USA). Reverse transcription was 
performed using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems, 
Foster City, CA, USA). TaqMan assays (Applied Biosystems) were used to obtain CT 
values and the ΔΔCT method was used to calculate the relative quantities of mig6, gapdh, 
or NOS2 mRNA. Primer sequences were described previously [222]. PCR reactions were 
performed in triplicate for each sample from at least three independent experiments and 
normalized to Gapdh mRNA levels.  
Statistical analyses  
All data are presented as means ± SEM. Protein and mRNA data were normalized 
to control conditions and presented as relative expression. The Student’s t-test (unpaired, 
two-tailed unless stated otherwise) or ANOVA (with Bonferroni post hoc tests) were 
performed using GraphPad Prism software (La Jolla, CA, USA) to detect statistical 
differences. p < 0.05 was considered statistically significant.  
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CHAPTER 5. DISCUSSION AND FUTURE STUDIES 
 
Currently, autoimmune-mediated β cell ablation is irreversible and results in overt 
T1D. Cellular therapeutic strategies to increase β cell mass are a promising avenue to 
bypass current drawbacks of immunotherapies. Theoretically, targeted β cell expansion 
strategies together with re-education of immune cells to stop β cell destruction could be 
immensely successful in treating or even curing T1D. Yet, there are fundamental gaps in 
our understanding of both underlying mechanisms, thereby keeping this kind of therapy 
still very far away. EGFR has been strongly implicated in β cell preservation, but aberrant 
EGFR signaling is a deterrent for its use in clinical settings. Mig6 is a prime candidate for 
indirect EGFR signaling modification. We suggest that Mig6 has a role in both pancreas 
development and the progression to diabetes. From the data collected in this dissertation, 
I propose that Mig6 is a switch for duct progenitor cell differentiation. This notion is 
based on our findings in Chapters 2 and 4.  
In Chapter 2, we demonstrated that a knock down in zebrafish mig6 resulted in 
truncated exocrine pancreas development, fewer endocrine cells, and an enlarged EPD. 
These data, in conjunction with previous Mig6 studies in the developing embryo [181], 
suggest that there is a pool of duct progenitor cells that, normally, give rise to a variety of 
further differentiated cell types. Yet, without the actions of mig6, these progenitors may 
prematurely differentiate and become quiescent, reducing the number of endocrine cells 
by preferential differentiation of early pancreatic progenitor cells to non-endocrine duct 
cells. Future studies would confirm the developmental phenotype in CRISPR-generated 
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mutants, and attempt to rescue the mig6MO developmental phenotype with EGFR 
inhibitor injections. 
Work in our lab has previously reported protection of STZ-induced β cell 
destruction in Mig6 heterozygous whole-body knock out mice [105]. We further refined 
our mouse model by creating a pancreas-specific Mig6 knock out mouse. Of course, 
between the tissue-specific Mig6 knock down in the mouse pancreas and the whole-body 
knock down of mig6 in zebrafish, the Mig6 PKO model provides a more precise account 
of the function of Mig6 in the pancreas, as the zebrafish pancreas phenotype may be a 
secondary effect of mig6 knock down in peripheral tissues such as liver or heart. In any 
case, whole-body knock down of Mig6 is probably not a translatable therapy to humans, 
as homozygous Mig6 knock out mice readily develop tumors [239-241]. More likely, 
targeting tissue-specific or cell-specific changes in Mig6 would be a more practical 
means to induce β cell regeneration. Efforts to develop targeted therapeutics continue to 
develop rapidly [242]. 
I speculate that Mig6 PKO mice have intact ductal progenitor cells due to 
incomplete knock down of Mig6. In Chapter 4, we observed increased β cell 
proliferation in response to STZ treatment in the Mig6 PKO mice. If the effects of Mig6 
on progenitor cell differentiation were unnoticed due to insufficient knock down, then 
integration of our findings in Chapter 2 leads us to hypothesize that a significant 
progenitor pool in the mouse pancreatic ducts was not altered and remained available for 
cell specification when subjected to β cell toxins. Contributing to this hypothesis is the 
observed increase in ventral bud-derived β cells in the zebrafish, which could signify an 
increased rate of proliferation or transdifferentiation in response to insufficient β cell 
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differentiation from pancreas progenitor cells. It is necessary to bring attention to the 
trending reduction (although not significant) in dorsal bud-derived β cells in the 
generation of this hypothesis. 
Future studies will elaborate on these findings by using a heat-shock inducible 
Cas9 to generate an inducible mig6 CRISPR mutant, to study the effect of mig6 without 
disrupting pancreas development. Using this model, we may see a similar increase in β 
cell regeneration in mig6 knock down as we saw in the Mig6 PKO mice.   
At first glance, our results in Chapter 4 would indicate a different role for mouse 
Mig6 in endocrine cell fate. We did not observe a change in β cell mass between control 
and Mig6 knock out mice as we did in the zebrafish. It is reasonable to assume because of 
the knock down efficiency in the mouse, there was functional Mig6 protein during key 
stages of development whose effects were uncovered only in the presence of β cell injury. 
If we assume our initial hypothesis from Chapter 3 is accurate, that Src kinase activation 
results in increased p-Mig6, we might gather that the rise in EGFR signaling observed in 
Figure 3-4 C was a result of decreased Mig6 activity, and this was only detected under 
cell stress conditions. This result would complement the β cell mass preservation in our 
Mig6 PKO mice treated with STZ.  
In Chapter 3, we investigated the facilitative effects of Src kinase, a possible 
regulator of Mig6 activity. We recapitulated, in the 832/13 cells and in isolated mouse 
islets, that Src kinase was activated under treatments with high glucose or cytokines. 
Further studies and alternative techniques are required to answer the questions posed in 
Chapter 3. Whereas all of the experiments in Chapter 3 focused on Src inhibition, Src 
overexpression would complement and perhaps enhance the data. However, because 
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overexpression of native Src itself may not correlate with increased activated Src, we 
would be relying on cytokine treatment and EGF stimulation to induce stoichiometric 
increases in phosphorylated Src. Instead transducing 832/13 cells with Ad-CMV-Src529, 
a constitutively active form of Src, would be more informative.  Src529 is an Y529F 
mutant that prevents the normal downregulation of kinase activity and thus results in 
unregulated kinase activity of Src [243]. 
Taken together, these data implicate Mig6 in at least two approaches to β cell 
restoration. First, Mig6 is required for proper differentiation of duct progenitor cells into 
endocrine cells, a mechanism with significant potential in β cell regeneration strategies 
(like the creation of stem cell-derived β-like cells or increasing endogenous β cell 
regeneration potential). And second, Mig6 blocks β cell proliferation through inhibition 
of EGFR-mediated recovery programs. Targeted ablation of Mig6 in the pancreas could 
sufficiently increase β cell mass during the honeymoon phase. Thus, Mig6 should be 
considered a prominent candidate for the treatment of diabetes. Not only could Mig6 
command pancreatic differentiation to generate β-like cells (in vivo, or in vitro), but Mig6 
also presents a promising cellular therapeutic alternative that, when used to target β cell 
recovery programs like EGFR, may restore β cell mass and reverse diabetes. 
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